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INTRODUCTION 
 
Administering a drug by the parenteral route has the advantages of 
bypassing the absorption process and the first-pass metabolism, thereby 
maximizing the bioavailability. For this reason, such a route is still the most 
used for administration of macromolecular drugs.  
Parenteral administration, however, has the disadvantage of being 
invasive, and hence, hardly accepted by the patient. Also, with cancer 
drugs it generates serious toxicity problems. On the other hand, the oral 
route, which is the most accepted by the patients as noninvasive and 
practical, has the inconveniences of requiring a prompt absorption of the 
drug, and of exposing it to the harsh conditions of the stomach and to 
metabolic degradation processes, including hepatic firstpass metabolism, 
which limits the bioavailability of many drugs, such as cardiovascular 
drugs, analgesics, and peptides.  
Drug administration via the nasal, buccal, vaginal, and ocular 
mucosae is noninvasive, is not subjected to hepatic first-pass metabolism 
and harsh environmental conditions, and further, mucosal surfaces are 
readily accessible. These benefits have prompted the numerous studies 
that have been carried out in recent years on transmucosal drug 
absorption. Generally, hydrophilic drugs that cross the epithelia via the 
paracellular route, such as, for example, peptides and proteins, have a 
poor permeability across the membrane, resulting in insufficient 
bioavailability. Therefore, reversible modifications of the drug molecule, for 
example, by making a permeable prodrug, or of the epithelial barrier 
structure, for example, by permeation enhancers, are required.  
The approaches that have been, and are currently being 
investigated for transepithelial drug delivery have very recently been 
discussed by Majumdar and Mitra [1]. Other recent reviews deal with the 
issues relevant to the optimization of absorption across specific mucosal 
surfaces, such as the intestinal [2], nasal [3,4], buccal [5-8] and ocular [9] 
ones, or to the paracellular penetration enhancement via modulation of the 
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tight junctions connecting epithelial cells [10-12]. Low molecular weight 
enhancers have been studied and applied for the last two decades (fatty 
acids, glycerides, chelators) or for longer (bile salts, surfactants). More 
recent are the studies on high molecular weight enhancers, in fact, the first 
report on the transmucosal absorption-enhancing properties of a 
semisynthetic polymer, chitosan, dates back to 1994 [17]. Since then, 
numerous studies have been carried out to evaluate the efficacy of 
polymeric absorption enhancers, their mechanisms of action, their 
structure-activity relationships and their safety. In regard to the last of 
these issues, it is observed that, unlike the low molecular weight 
enhancers, the physicochemical characteristics of which favor their own 
absorption, high molecular weight polymers are generally not absorbed, 
and this minimizes the risk of systemic toxicity. Another important 
advantage of macromolecular enhancers over small molecular weight 
compounds resides in the fact that most of the former have mucoadhesive 
properties, which often act in synergism with the permeability-enhancing 
ones by facilitating and prolonging contact of the polymer molecule with 
the epithelium surface.  
The enormous potential of the enhancer approach to an effective, 
comfortable, and safe transmucosal administration of challenging drugs 
has stimulated an ever-increasing interest in putting to test new 
prospective polymeric enhancers.  
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SECTION I - Novel quaternary ammonium chitosan 
derivatives for the promotion of intraocular drug 
absorption 
 
I.1. Introduction 
Topical, non-invasive drug treatment of the anterior chamber of the 
eye requires an effective intraocular drug absorption. Hence, the 
importance of non-irritant, non-toxic and efficient transcorneal drug 
penetration enhancers is clearly apparent. Chitosan, a biocompatible and 
biodegradable polymer obtained by deacetylation of chitin, has increased 
the absorption of a number of hydrophilic compounds and peptide drugs 
across the intestinal [13-16], nasal [17], and buccal [18] epithelia. Also, the 
ability of chitosan hydrochloride to facilitate the buccal and vaginal 
absorption of acyclovir [19] and the transcorneal penetration of the poorly 
water-soluble antibiotic ofloxacin into the aqueous humour of rabbit eyes 
[20] was demonstrated. From here it descends that chitosan can enhance 
drug absorption across not only epithelial cell monolayers, but also 
stratified epithelia, such as the cornea. The effectiveness of chitosan as an 
absorption enhancer, however, is severely limited by its insolubility at the 
neutral pH of most physiological environments [22]. This inconvenience 
was circumvented by synthesizing the partially quaternized derivative N-
trimethylchitosan chloride (TMC), which is soluble irrespective of pH. 
Indeed, it has proved an effective permeation enhancer of hydrophilic 
molecules and macromolecules across intestinal and buccal epithelia [23-
26] as well as of ofloxacin and dexamethasone across the cornea [20, 27] 
in neutral environments. It was reported that chitosan and TMC act on the 
epithelium through an interaction of the polycationic polymers with the 
negatively charged sites on the cell membrane and/or in the tight junctions 
joining epithelial cells [13, 23, 24, 28-30]. Consequently, it was thought 
that the absorption-enhancing efficacy of TMC could depend on its charge 
density which, in neutral or alkaline environments, is determined by its 
quaternization degree [30]. In the light of the above information, novel 
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chitosan derivatives with pendant quaternary ammonium groups were 
prepared by reacting chitosan with 2-diethylaminoethyl chloride (DEAE-Cl) 
under different conditions [31]. The general structure of these derivatives, 
assessed by NMR analysis, is depicted in Figure 1. Their substitution 
degree and number of adjacent quaternary ammonium groups in the 
pendant short chains was shown to depend on the molar ratio between the 
reactant DEAE-Cl and the chitosan repeating unit, used in the synthesis. 
The ability of such derivatives to promote the penetration of hydrophobic 
(rhodamine 123) as well as hydrophilic (fluorescein sodium) drug models 
across the excised porcine buccal mucosa was evidenced [31]. Hence, 
these polymers show promise of behaving as penetration enhancers of 
different drugs across different epithelia. 
The aim of the present work has been the study of the potential of 
the above quaternary ammonium derivatives of chitosan to enhance 
intraocular drug absorption via either the transcellular or the paracellular 
transport route. To this purpose, the hydrophobic dexamethasone (log P = 
1.95, according to Leo et al. [32]) was chosen as the marker of the 
transcellular transcorneal absorption route, and also because it is 
commonly used to treat the inflammation of the ocular anterior segment, 
while the polar fluorescein sodium was chosen as the marker of the 
paracellular route. The latter molecule has already been used for the 
above function, although the epithelium under study was the intestinal [33] 
or the buccal [31] one. The effects of chitosan derivatives having different 
degrees of substitution and numbers of quaternary ammonium groups in 
the pendant chains, on the permeability of each marker across the excised 
rabbit cornea have been assessed and compared with the effect of the 
known penetration enhancer, TMC. A confirmation of the permeability 
enhancing effect has been sought in vivo, by comparing the 
pharmacokinetics in the precorneal area and in the aqueous of the rabbit 
eyes following instillation of isoviscous medicated eyedrops containing or 
not the more representative enhancer. 
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I.2. Materials and methods 
I.2.1 Materials 
Fluorescein sodium salt (NaFlu) and dexamethasone (DMS) 
(Sigma); 2-diethylaminoethyl chloride (DEAE-Cl) hydrochloride and 
poly(vinyl alcohol) 72000 (PVA) (Fluka); chitosan (minimum 90% 
deacetylated) from shrimp shell (ChS) (Chito-clear FG90, Primex, 
Drammen, Norway) were used. The commercial ChS had an average 
viscometric molecular weight of 590 kDa. The deacetylation degree 
determined by IR or NMR was 90% or 82%. TMC with a quaternization 
degree of 46% was prepared from ChS by an already described method 
[20]. 
 
I.2.2 Diethylaminoalkylation of chitosan 
The diethylaminoalkylation of chitosan was carried out as described 
in a previous paper [31]. Two grams of the commercial ChS powder were 
dissolved in 80 ml of 0.11 M hydrochloric acid (pH 4.7). For the reaction, 4 
or 8 g DEAE-Cl HCl, and 11 ml of 15% sodium hydroxide were added in 
sequence to the chitosan solution, under vigorous stirring at 60-65°C. The 
molar ratio between DEAE-Cl and the ChS repeating unit was 2, or 4. 
Following the addition of the sodium hydroxide solution, a mucilage was 
formed, which dissolved in about 5 min. Stirring and heating were 
continued for a total of 2 h, during which the pH was kept at about 8 by 
repeatedly adding sodium hydroxide pellets. Then, the reaction mixture 
was made to pH 7, by adding 1 M hydrochloric acid, and clarified by 
filtration through filter paper under vacuum. Then it was purified by dialysis 
(Spectra/Por, cut-off 3500, Spectrum Laboratories Inc., Rancho 
Dominguez, CA, USA) under sink conditions. The dialysis was continued 
until no chloride was found in the external phase, then the internal solution 
was lyophilized. According to the NMR analysis described in the previous 
paper [31] the derivative obtained from the reaction of ChS with DEAE-Cl 
in the 1:2 molar ratio had a degree of substitution of 40% and an average 
of 1.6 quaternary ammonium groups in the pendant chains (N+-ChS-2), 
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while the derivative resulting from the 1:4 molar ratio between the ChS 
repeating unit and DEAE-Cl had a degree of substitution of 132% and an 
average of 2.5 quaternary ammonium groups in the pendant chains (N+-
ChS-4).  
 
I.2.3 Permeation measurements across excised rabbit cornea 
Male, New Zealand albino rabbits of 2.5-3.0 kg were used. They 
were treated as prescribed in the publication ‘Guide for the care and use 
of laboratory animals’ (NIH Publication No. 92-93, revised 1985). All 
experiments were carried out under veterinary supervision, and the 
protocols were approved by the Ethical-Scientific Commitee of the 
University.  
The rabbits were euthanized with intravenous pentobarbital 
(Pentothal sodium, Farmaceutici Gellini, Aprilia, Italy). The eyes were 
proptosed, and the corneas, with a 2 mm ring of sclera, were immediately 
excised and mounted in perfusion cells fabricated according to Camber 
[34]. The corneal area available for diffusion was 0.78 cm2. The cell was 
maintained at 35 ± 1°C. Preheated glutathione bicarbonate Ringer buffer 
pH 6.8 (GBR) was added to both the donor (1.0 ml) and the receptor (3.0 
ml) compartment. To ensure oxygenation and agitation, an O2-CO2 (95:5) 
mixture was bubbled through each compartment at a rate of 3-4 bubble/s. 
After 10-min equilibration, the solution in the donor side was replaced with 
1.0 ml of a solution (NaFlu) or a suspension (DMS) of the test substance 
0.3% w/v in GBR (control), or of such a mixture containing 1% w/v of the 
polymer under test. At appropriate time intervals, 100 µl of the receptor 
solution was withdrawn for analysis, and replaced with an equal volume of 
fresh preheated buffer. Each experiment had a 4.0-h duration, and was 
repeated at least 6 times.  
 
I.2.4 Gravimetric evaluation of corneal hydration levels 
At the end of each permeation run the cornea was removed from 
the perfusion apparatus and the percent corneal hydration level was 
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evaluated by measuring the total water content of the cornea by 
desiccation. After carefully removing the remaining sclera the trimmed 
cornea was gently blotted dry and the wet corneal weight (Ww) was 
determined (10-5 g). The sample was then desiccated in an oven at 100°C 
for 6 h after which it attained a constant weight (dry corneal weight, Wd). 
The percent corneal hydration level (HL%) was calculated as 
[1−(Wd/Ww)]100. 
 
I.2.5 Preparation of ophthalmic drops 
For in vivo tests, the following ophthalmic drops were prepared: 
0.3% w/v NaFlu, 1% w/v N+-ChS-4, 4.3% w/v poly(vinyl alcohol) (PVA) in 
phosphate buffer pH 7.4, 0.0375 M made isotonic with sodium chloride 
(PB) (code, NaFlu Sample); 0.3% w/v NaFlu, 5.5% w/v PVA in PB (code, 
NaFlu Reference); 0.3% w/v DMS, 1% w/v N+-ChS-4, 4.3% w/v PVA in PB 
(code, DMS Sample); 0.3% w/v DMS, 5.5% w/v PVA in PB (code, DMS 
Reference). The DMS drops contained a dispersion of drug particles (< 1.5 
µm) obtained by spray-drying a 0.1 mg/ml drug solution (Mini Spray Dryer 
BÜCHI B-191, inlet and outlet air temperatures, 150°C and 60°C, 
respectively; spray nozzle, 0.7 mm; feed flow, 8 ml/min). The osmolality of 
the drops, measured by a microosmometer (Hermann Roebling, Berlin) 
ranged between 398 and 412 mOsm/Kg. Rheograms of the drops were 
recorded at 35°C with a Haake RS1 rheometer, equipped with the coaxial 
cylinders Z40 (rotor) and Z41 (stator). Data were acquired and analyzed 
by Rheo Win Pro software (Haake). 
 
I.2.6 Assessment of NaFlu-polymer interactions 
A previously described method, based on the dynamic dialysis 
technique [20], was used to determine the NaFlu-polymer interactions in 
the donor phases of the permeation measurements and in the ophthalmic 
drops, at 35°C. Permeant flux through a porous cellulose membrane 
(Spectra/Por, molecular weight cutoff, 3500 Da, Spectrum Laboratories 
Inc., Rancho Dominguez, CA) under quasi-steady state conditions was 
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measured in the presence or absence of the polymer in the donor phase. 
The NaFlu initial concentration was equal to that used in the ex vivo and in 
vivo experiments, i.e., 0.3% w/v. Sink conditions were ensured in the 
receptor medium, which contained the same solutes at the same 
concentrations as the donor, except for the permeant and the polymer, in 
order to prevent volume variations due to osmosis. The receptor was 
analysed for NaFlu by an already described HPLC method [27]. The 
regression for the fitting of dialysis data, expressed as drug concentration 
in the donor vs. time, to 1st order kinetics was always significant (r2≥0.987, 
n≥8). This allowed calculation of the dialysis rate constant. Under the 
above experimental conditions, a reduction of the dialysis rate constant 
caused by the polymers was considered a sign and a measure of 
permeant-polymer interactions. The fraction of non-interacting permeant, 
fF, was expressed by the following equation [35]:  
a
p
F k
k
f =                              Eq. I.1. 
where kp and ka represent the dialysis constants in the presence and in the 
absence of polymer, respectively. 
Differences between the determined values of kp and ka were considered 
significant, on the basis of the Student's t-test, at P < 0.05. 
 
I.2.7 Permeation data treatment 
For each permeation run a value of the apparent permeability 
coefficient, P*app, of permeant across the cornea was calculated from the 
following equation, assuming passive diffusion under steady-state 
conditions: 
F0
app* fAC
1
dt
dMP =                  Eq. I.2. 
where: 
A
1
dt
dM
, the permeation flux, is the slope of the linear portion of the 
cumulative amount permeated per unit surface area vs. time plot, C0 is the 
initial concentration of the permeant dissolved in the donor solution, and fF 
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has already been defined in Eq. I.1. In the case of DMS, which was 
present in the donor as a suspension, the product C0fF is theoretically 
equal to the drug solubility in the donor phase (0.12 mg/ml), whatever the 
DMS-polymer binding. For each plot, the linear regression analysis was 
extended to the set of data points that gave the best fit, as judged from the 
r2 value. Also the lag time, L*, that is the time axis intercept of the 
regression line, was calculated for each plot. The single P*app and L* 
values were averaged to calculate the mean apparent permeability, Papp 
and the mean lag time, L (n=6). The mean cumulative amount permeated 
per unit area at any given time was calculated to plot each permeation 
profile and to determine T4h, i.e., the cumulative transport over the whole 
time of experiment. The significance of the difference between two Papp, or 
L, or T4h values was assessed by the Student’s t-test (P < 0.05). For the 
chitosan derivatives that produced a significant Papp increase, this was 
measured by the enhancement ratio (ER), defined as the ratio between 
the Papp values obtained in the presence and in the absence of the 
enhancer. 
 
I.2.8 In vivo tests 
Male, New Zealand albino rabbits of 2.5-3.0 kg were used. To 
evaluate the rabbit eye irritation caused by the ophthalmic drops under 
study, a modified Draize test was carried out [36]. Two drops (50 µl each), 
corresponding to 0.3 mg of NaFlu or DMS, were instilled at 1 min intervals 
into the lower conjunctival sac of the rabbits, with care to avoid spillage. 
For determination of the kinetics of NaFlu or DMS disappearance from tear 
fluid, at intervals tear fluid samples were collected from the lower marginal 
tear strip using 1.0 µl disposable glass capillaries (Microcaps, Drummond 
Scientific Co., U.S.A.) flushed with 1.0 µl water. After further dilution with 
100 µl water the samples were directly injected for analysis by HPLC [27, 
31]. Data were obtained from six eyes. For measurement of NaFlu or DMS 
transcorneal penetration, after pre-established times from instillation the 
rabbits were anaesthetized, then 60-80 µl of aqueous humour were 
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aspirated from the anterior chamber, using a 1.0 ml insulin syringe fitted 
with a 29 gauge needle. At least six animals were used for each time 
point. For analysis, each sample was mixed with an equal volume of 
acetonitrile, then it was centrifuged and 20 µl of the supernatant were 
analized by HPLC [27, 31]. The area under the concentration in aqueous 
humour versus time curve (AUC), was calculated by the linear trapezoidal 
rule, between 0 and 180 min for NaFlu, and between 0 and 150 min for 
DMS. Reported statistical methods were used in comparing AUC values 
[37]. The significance of differences between pharmacokinetic parameters 
was evaluated by the Student's t-test (p < 0.05). 
 
I.3 Results and discussion 
 
I.3.1 Permeation studies 
The experimental model used to determine the corneal permeability 
has been demonstrated by previous reports to be valid [34, 38]. The 
hydration level (HL%) of the corneal tissue has been considered a 
sensitive indicator of tissue integrity. According to the literature, the normal 
water content of the rabbit cornea ranges between 75% and 78% (see, 
e.g., ref. 39) a corneal damage being indicated by hydration levels 
increased to 83% or more [38]. In the present work the corneal hydration 
was determined, at the end of each permeation run, by the usual 
gravimetric method [38, 40-41]. The resulting HL% values are listed in 
Tables I.1. and I.2. None of them is higher than the value of 80.1±0.69%, 
reported by Monti et al. [38] for freshly excised rabbit corneas, which 
indicates that neither the permeants nor the chitosan derivatives produced 
any substantial damage to the tissue in the perfusion apparatus. The 
effects of chitosan derivatives on the epithelium permeability may stem 
from polymer interactions not only with the epithelium structures, but also 
with the permeant in the donor solution. Indeed, the latter interaction type 
might depress the permeability in that the permeant fraction bound to the 
polymer can be considered impermeable. The concentration of the 
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permeant fraction free from interactions with the polymer, represented by 
the product C0fF, was introduced into Eq. I.2., so that the calculated 
permeability values are independent of binding and only reflect polymer 
interactions with the epithelium. 
 
I.3.1.1 Permeation of DMS 
The data on DMS permeation in the absence (control) or in the 
presence of each of the chitosan derivatives under study (1% w/v) are 
presented in Figure I.2., while the relevant parameters are listed in Table 
I.1. All regressions, applied to the linear portion of each plot, are significant 
(r2 > 0.99). As appears from the values of Papp, calculated as illustrated in 
Section I.2.7, this property was significantly enhanced by the chitosan 
derivatives with respect to the control, the difference in the extent of 
enhancement between different polymers being not significant. Also the 
lag time preceding the attainment of steady-state permeation was 
significantly increased by the polymers, which suggests that a time longer 
than the control lag time was required for the permeability enhancing effect 
to reach its maximum intensity. The L values seen in Table I.1. for the 
different chitosan derivatives are significantly different from one another, 
the value for N+-ChS-4 being the shortest. In fact, with this polymer the 
total transport over the whole time of experiment is the maximum of all 
cases. Then, although the chitosan derivatives tested produced about the 
same enhancement of DMS corneal permeability at steady state, N+-ChS-
4 has shown the best potential as an intraocular DMS absorption promoter 
in virtue of the comparative rapidity of its effect. This is particularly 
important if the short contact times usually allowed by eyedrops is 
considered. Since DMS is supposed to cross the cornea via the 
transcellular route, the enhancement effect may be thought to result from 
a strong interaction between the pendant quaternary ammonium groups of 
N+-ChS-4 and the negatively charged cell surface, which would perturb the 
order of the membrane lipid bilayers. 
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I.3.1.2 Permeation of NaFlu 
The data on NaFlu permeation in the absence or in the presence of 
each of the chitosan derivatives under study (1% w/v) are presented in 
Figure I.3., while the relevant parameters are listed in Table I.2. All 
regressions, applied to the linear portion of each plot, were significant (r2 > 
0.99). This allowed calculating flux and Papp values for each experiment 
type, according to the criteria illustrated in Section I.2.7. The Papp value for 
the NaFlu control (absence of chitosan derivatives from the donor) is one 
order of magnitude lower than that for the DMS control, as results from a 
comparison of relevant data in Tables I.1. and I.2. If NaFlu is supposed to 
cross the cornea via the paracellular route, these data would indicate that 
this route is much less pervious to the polar NaFlu than the transcellular 
route is to the non-polar DMS. The fF values in Table I.2. testify to a 
significant NaFlu binding by the chitosan derivatives, ascribed to an ionic 
interaction between the anionic NaFlu and the polycationic polymers. This 
was accounted for by calculating the relevant Papp values by means of Eq. 
I.2. Such values, listed in Table I.2., along with the corresponding ones for 
DMS, seen in Table I.1., indicate that the present chitosan derivatives are 
able to effectively enhance the corneal permeability of highly polar 
molecules, such as NaFlu, as well as that of non-polar ones, such as 
DMS. Unlike in the case of DMS, where the different chitosan derivatives 
exerted much the same effect on corneal permeability, the enhanced Papp 
values for NaFlu appear in Table I.2. to be significantly different from one 
another, the enhancers ranking in the following order of effectiveness: N+-
ChS-4 > TMC > N+-ChS-2. This difference between DMS and NaFlu could 
be explained by assuming that the polymers would enhance the 
permeability of NaFlu by acting on corneal structures (i.e., the tight 
junctions) different from those supposed to control the permeation of DMS 
(i.e., the cell membranes). Although the relevant ER values indicate that 
the enhancing effects on NaFlu permeability are always remarkably 
stronger than those exerted on DMS, yet in no case did the resulting Papp 
values for NaFlu exceed the value for the DMS control. These findings 
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suggest that the transcellular route across the cornea is much more 
pervious to non-polar drugs than the paracellular route is to highly polar 
ones, despite the enhancing effect exerted on the latter by the present 
chitosan derivatives. As stated in the foregoing discussion, the Papp values 
for NaFlu were calculated by Eq. I.2. in order to separate the effects of the 
enhancers on the corneal structures from those exerted on permeability by 
the NaFlu-polymer binding. Such a binding would counteract the Papp 
enhancing effect, and therefore, the flux and T4h values produced by N+-
ChS-4 were not significantly different from those produced by TMC, 
despite the significantly higher Papp value for the former, because N+-ChS-
4 exerted a stronger binding and allowed a lower fF compared to TMC. 
The L values for the chitosan derivatives, seen in Table I.2., are close to 
the value for the control, which indicates that the time required by the 
polymers to exert their enhancing effects was hardly longer than that 
required for attaining steady-state permeation conditions. This prevents 
any evaluation of the promptness of the effects, based on the L value. 
 
I.3.2 Formulation of solutions for in vivo tests 
The corneal permeability enhancing effects of the chitosan 
derivatives, evidenced by the ex vivo permeation experiments discussed 
in the preceding section, are per se insufficient to anticipate effective 
transcorneal absorption enhancements in vivo, because some time may 
be required for the enhancers to be effective, while the contact times 
allowed by eyedrops are rather short. Thus, in vivo tests were carried out 
to verify, in the rabbit model, the ocular tolerability and the efficacy of N+-
ChS-4, which has proved the more effective permeability enhancer. The 
viscosity of the ophthalmic drops containing the polymer under test was 
increased by adding PVA, a polymer known to be inert on the cornea. By 
this means the residence of model drug and enhancer in the precorneal 
area was prolonged by reducing tear fluid drainage. The relevant 
rheograms (not shown) exhibited a pseudoplastic behaviour, appropriate 
for ophthalmic solutions. The viscosity of Samples and respective 
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References was made similar in order to equalize the residence time of 
the permeants in the precorneal area. Under this condition the N+-ChS-4 
effect on the pharmacokinetics in the aqueous could solely be ascribed to 
a corneal permeability enhancement [20]. The viscosity values at 35 °C 
and 100 s-1 were: 28.28 mPas, for NaFlu Sample; 27.50 mPas for DMS 
Sample; 20.05 mPas for NaFlu Reference; 19.75 mPas for DMS 
Reference.  
 
I.3.3 In vivo tests 
The modified Draize test [40] revealed a slight conjunctival 
discharge and a very slight reddening of the conjunctiva, but no chemosis, 
during the first 30 min after application of the Samples. In none of the six 
rabbits did the Iirr score exceed 3. Then, on the whole N+-ChS-4 exhibited 
a fair ocular tolerability. As appears from Figure I.4. the lacrimal clearance 
was similar for each Sample and the respective Reference. This elicited 
evidencing the transcorneal penetration enhancing effect of the polymer 
via its effect on the pharmacokinetics in the aqueous. The lachrimal 
clearance of DMS was faster than that of NaFlu, possibly because the 
suspended DMS particles caused a more frequent lachrimal turnover. The 
concentration vs. time profiles in the aqueous are compared in Figure 5 
while the pharmacokinetic data are listed in Table I.3. DMS Reference 
shows a much higher intraocular availability than NaFlu Reference, 
essentially due to a much more favourable partitioning of the lipophilic 
DMS into the corneal cell membrane. DMS Sample produced a significant 
enhancement of DMS intraocular absorption, in agreement with the 
significant increase of DMS permeability across the excised cornea 
produced by N+-ChS-4 in the course of the ex vivo experiments discussed 
in Section 1.3.1.1. The polymer is unlikely to produce this effect by 
improving drug partitioning into the cornea, but rather, it is likely to 
facilitate transcellular DMS transport by perturbing the lipid bilayers of the 
corneal cell membranes. The data show that NaFlu transcorneal 
penetration from NaFlu Reference is almost insignificant, mostly because 
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of an unfavourable distribution of the very hydrophilic permeant into the 
cornea, further depressed by the binding of 52% NaFlu molecules by the 
PVA contained in NaFlu Reference. The presence of N+-ChS-4 in NaFlu 
Sample increased the NaFlu bound fraction to 76%, as shown by the 
dynamic dialysis measurements. Nevertheless, N+-ChS-4 in NaFlu Sample 
remarkably enhanced intraocular absorption, as shown by the relevant 
Cmax, AUC and AUCrel values. This result confirms the N+-ChS-4 ability to 
enhance NaFlu corneal permeability, evidenced by the ex vivo 
experiments and ascribed to a loosening of the tight junctions between 
corneal cells. In fact, there is an overall agreement between the results of 
the ex vivo experiments, found in Tables I.1. and I.2. and those of the in 
vivo ones, found in Table I.3.. The enhancement effect exerted on corneal 
permeability by N+-ChS-4 is seen from the relevant ER values to be 
remarkably stronger for NaFlu than for DMS. Yet, the enhanced Papp of 
NaFlu remains lower than the not enhanced (control) Papp of DMS. In 
agreement with these results, the AUCrel value, which measures the N+-
ChS-4 effect on the intraocular availability of DMS or NaFlu, is remarkably 
higher for the latter than for the former, yet the enhanced AUC and Cmax 
values for NaFlu remain lower than the respective not enhanced values for 
DMS. It should be recognized, in this respect, that different AUC and Cmax 
values for two different permeants are suggestive of differences in corneal 
permeability, even though other pharmacokinetic parameters may be 
different. It may be noticed that the concentration vs. time curves in the 
aqueous, seen in Figure I.5., show an initially rapid absorption with no 
evident lag time, in apparent contrast with the ex vivo data presented in 
Figures I.2. and I.3. and in Tables I.1. and I.2.  
Such an apparent contradiction can be solved as follows. A lag time 
is needed to attain steady-state flux across the excised cornea in the ex 
vivo experiments, where steady-state conditions are ensured by a time-
constant permeant concentration in the donor. On the other hand, in the in 
vivo tests the permeant concentration at the absorption site is maximal at 
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the beginning of contact, and declines rapidly, as appears from the 
concentration vs. time plots in tear fluid, seen in Figure I.4.  
 
I.4 Conclusions  
The ex vivo and in vivo experiments have concurrently put into 
evidence the potential of substituted chitosans of the N,O-[N,N-
diethylaminomethyl(diethyldimethylene ammonium)nmethyl] type to 
enhance the corneal permeability, and hence, the intraocular penetration 
of either non-polar or highly polar drugs. N+-ChS-4, the more substituted 
derivative with the higher positive charge density has resulted more 
effective than TMC, the well known transepithelial absorption enhancer, 
and has shown a fair ocular tolerability. Because DMS, taken as a model 
of non-polar drugs, and NaFlu, model of highly polar ones, are supposed 
to cross the cornea via the transcellular and the paracellular route, 
respectively, then N+-ChS-4 is believed to act both by perturbing the order 
of the lipid bilayers of the cell membrane and by loosening the tight 
junctions joining the corneal cells. The paracellular route remains 
comparatively difficult to penetrate, despite the enhancing effect of N+-
ChS-4. Indeed, although the effect on NaFlu corneal permeability and 
intraocular availability is stronger than that exerted on the respective 
properties of DMS, still the enhanced permeability and intraocular 
availability of the polar molecule have resulted lower than the 
corresponding, not enhanced properties of the non-polar one. It must be 
considered, nevertheless, that the anionic NaFlu was partially bound by 
the polycationic N+-ChS-4. Although the relevant permeability value is 
independent of the binding, since it was calculated on the free NaFlu 
fraction basis, the transcorneal flux, and hence, the intraocular availability 
could have been depressed by the binding. Then, the effect of N+-ChS-4 
on the intraocular transport of a polar drug not interacting with the polymer 
(e.g., a cationic one) may be expected to be stronger than that evidenced 
in the present work with NaFlu. 
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TABLES  
 
Table I.1. - Data on DMS permeation across excised rabbit cornea from GBR containing 
0.3% w/v DMS and 1% w/v of different chitosan derivatives (mean ± SD, n = 6). 
Polymer HL%a Flux  
(µg cm-2 h-1) 
Lb (h) Pappc 106 
(cm s-1) 
ERd T4he  
(µg cm-2) 
Control 79.2±0.81 1.61±0.47 1.22±0.14 4.38±1.28 - 5.07±0.71 
TMC 79.1±0.85 3.43±0.44* 1.96±0.12* 7.94±1.02* 1.81 6.94±0.57* 
N+-ChS-2f 77.9±0.52 3.21±0.55* 1.51±0.11* 7.43±1.27* 1.70 8.23±1.13* 
N+-ChS-4f 78.7±0.73 3.49±0.24* 1.30±0.10 8.08±0.55* 1.84 9.59±1.42* 
aCorneal hydration level. 
bLag time. 
cApparent permeability. 
dEnhancement ratio. 
eCumulative transport over the whole time of experiment (4 h). 
fSee Figure I.1. and Section I.2.2. for polymer structure and explanation of polymer code. 
The data marked by * are significantly different from the respective controls (P < 0.05). 
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Table I.2. - Data on NaFlu permeation across excised rabbit cornea from GBR containing 
0.3% w/v NaFlu and 1% w/v of different chitosan derivatives (mean ± SD, n = 6). 
Polymer HL%a Flux  
(µg cm-2 h-1) 
Lb (h) fFc Pappd 107  
(cm s-1) 
ERe T4hf  
(µg cm-2) 
Control 78.7±0.69 2.14±0.66 1.85±0.05 - 1.98±0.61 - 4.56±1.32 
TMC 77.5±0.75 8.33±0.94* 2.14±0.03* 0.65 11.86±1.02* 5.99 15.65±1.67* 
N+-ChS-2g 78.8±0.66 4.39±0.24* 2.10±0.09* 0.62 6.55±0.36* 3.31 8.44±1.04* 
N+-ChS-4g 77.5±0.79 7.11±1.04* 2.17±0.04* 0.39 16.88±2.47* 8.52 13.22±2.22* 
aCorneal hydration level. 
bLag time. 
cNaFlu fraction free from polymer binding. 
dApparent permeability. 
eEnhancement ratio. 
fCumulative transport over the whole time of experiment (4 h). 
gSee Figure I.1. and Section I.2.2. for polymer structure and explanation of polymer code. 
The data marked by * are significantly different from the respective controls (P < 0.05).  
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Table I.3. - Pharmacokinetic data for the aqueous (mean ± SD, n ≥ 6)a. 
Vehiclea Cmax (µg ml-1) tmax (min) AUC (µg ml-1 min) AUCrel 
DMS Reference 0.214±0.030 60 17.13±2.17 1 
DMS Sample 0.407±0.052* 60 28.27±2.88* 1.65 
NaFlu Reference 0.023±0.006 90 2.37±0.56 1 
NaFlu Sample 0.102±0.021* 90 10.80±1.27* 4.56 
aSee Sections I.2.5., I.2.8. and I.3.3. for vehicle composition, in vivo tests and data 
discussion.  
The data marked by * are significantly different from the respective references (P < 0.05). 
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FIGURES  
 
 
 
 
 
 
 
 
 
Figure I.1. - Structure of N,O-[N,N-diethylaminomethyl(diethyldimethylene 
ammonium)nmethyl] chitosans. 
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Figure I.2. - Effects of chitosan derivatives on DMS permeation across excised rabbit 
cornea. Means ± SD of 6 runs. Regression lines are reported (r2 > 0.99). Explanation of 
polymer codes is found in Section I.2.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 1 2 3 4
0.0
2.5
5.0
7.5
10.0
12.5
Control
TMC
N+-ChS-4
N+-ChS-2
time (h)
am
ou
nt
 
pe
rm
ea
te
d 
( µg
/c
m
2 )
 22
 
 
 
 
Figure I.3. - Effects of chitosan derivatives on NaFlu permeation across excised rabbit 
cornea. Means ± SD of 6 runs. Regression lines are reported (r2 > 0.99). Explanation of 
polymer codes is found in Section I.2.2. 
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Figure I.4. - Kinetics of DMS and NaFlu disappearance from tear fluid following 
instillation of ophthalmic drops (see Section I.2.5. for vehicle composition). Means ± SD 
of at least 6 values obtained with different animals. 
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Figure I.5. - Pharmacokinetics in the aqueous following instillation of ophthalmic drops 
(see Section I.2.5. for vehicle composition). Means ± SD of at least 6 values obtained 
with different animals. 
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SECTION II - Improved synthesis of quaternary ammonium-
chitosan conjugates (N+-Ch) for enhanced intestinal drug 
permeation 
 
II.1 Introduction 
The ability of chitosan to promote drug absorption across different 
epithelia (intestinal, nasal, buccal, corneal) is now well documented [13-
20]. Chitosan has been partially quaternized to yield the watersoluble N-
trimethylchitosan chloride (TMC) [21] in order to circumvent the limits of 
chitosan insolubility at neutral pH. TMC has proved an effective drug 
permeation enhancer across intestinal, nasal, buccal, corneal epithelia in 
neutral environments [20, 23-27, 30, 46]. It was reported that the 
absorption-enhancing efficacy of TMC could depend on its charge density 
which, in neutral or alkaline environments, is determined by its degree of 
quaternization (DQ) [29, 30]. However, other structural properties of 
polymer must concur in determining its effectiveness, in fact, 
methyldiethylaminoethyl dextran, the fully quaternized derivative of 
diethylaminoethyl dextran [54], failed to enhance ofloxacin permeability 
across the reconstituted cornea [20]. It was also reported that 
mucoadhesion is a key element of TMC polymers for being effective as 
absorption enhancers at mucosal surfaces and that the mucoadhesivity of 
these polymers increases with increasing MW [52]. Then, on the basis of 
literature information it could be hypothesized that the transmucosal drug 
absorption enhancing properties of quaternized chitosans depend on MW, 
DQ and other structural features. In this light, novel chitosan derivatives 
with pendant quaternary ammonium groups were prepared by reacting 
chitosan with 2 diethylaminoethyl chloride (DEAE-Cl) under different 
conditions [31]. These derivatives were shown by NMR analysis to have 
the structure of quaternary ammonium-chitosan conjugates (N+-Ch), as 
depicted in Figure I.1. The ability of N+-Ch polymers to promote the 
penetration of hydrophobic (rhodamine 123) as well as hydrophilic 
(fluorescein sodium) drug models across the excised porcine buccal 
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mucosa was evidenced [31]. Such polymers have also shown the ability to 
enhance the permeability of the hydrophobic dexamethasone and that of 
the hydrophilic fluorescein sodium across the excised rabbit cornea, and 
to promote the intraocular absorption of these drug models in vivo, in the 
rabbit model [55]. The enhancing effects of N+-Ch polymers were found to 
be stronger than those of the known penetration enhancer, TMC [31, 55]. 
Hence, these polymers show promise of behaving as effective penetration 
enhancers for different drugs across different epithelia. The present work 
aims at extending the knowledge of the potential of N+-Ch polymers to 
safely promote transepithelial drug absorption. For the first time ever, in 
the present work selected polymers of the N+-Ch type have been tested on 
excised rat intestinal epithelium for their ability to promote penetration of 
two hydrophilic drug models, i.e., fluorescein sodium (low MW) and 
fluorescein isothiocyanate dextran (MW 4400 Da), and a lipophilic one, 
i.e., rhodamine 123, without causing any significant damage to the tissue. 
Fluorescein sodium and fluorescein isothiocyanate dextran are 
transported via the paracellular route, while rhodamine 123 is transported 
via both the paracellular and the transcellular routes [50]. In our previous 
work [31, 55] N+-Ch polymers, each obtained and characterized from a 
single batch, were studied. However, we subsequently verified that the 
reproducibility of the synthesis reaction was unsatisfactory, probably 
because the pH of the reaction mixture was not controlled strictly, in fact, it 
was let to vary during the reaction. Therefore, in the present development 
of the work the pH has been strictly controlled at 5, 6, 7, 8 or 9 over the 
reaction time, and the pH dependence of the DS and n values of product 
and process reproducibility have been assessed. By these means the 
polymer structure could be predetermined through a strict control of the 
synthesis conditions, namely, molar ratio between reactant DEAE-Cl and 
chitosan repeating unit, reaction temperature and pH. 
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II.2 Materials and methods 
 
II.2.1 Materials 
Fluorescein sodium salt (NaFlu), rhodamine 123 (Rh-123), 
fluorescein isothiocyanate dextran, MW 4400Da (FD4), trypan blue 
(Sigma); 2-diethylaminoethyl chloride (DEAE-Cl) hydrochloride (Fluka); 
chitosan (minimum 90% deacetylated) from shrimp shell (Ch) (Chito-clear 
FG90, Primex, Drammen, Norway) were used. The commercial Ch had an 
average viscometric molecular weight of 590 kDa. The deacetylation 
degree, determined by IR or NMR, was 90% or 82%. TMC with a DQ of 
46% was prepared from Ch by an already described method [20]. 
 
II.2.2 Controlled synthesis of N+-Ch polymers 
Two grams of commercial Ch powder were dissolved in 80 ml of 
0.11M hydrochloric acid (pH 4.7). Eight grams of DEAE-Cl HCl and 11 ml 
of 15% sodium hydroxide were added in sequence to the Ch solution, 
under vigorous stirring at 65°C. The molar ratio between DEAE-Cl and the 
Ch repeating unit was 4. Stirring and heating were continued for a total of 
2h during which the pH of the reaction mixture was kept under strict 
control at a pre-established value (5, 6, 7, 8 or 9) by keeping the electrode 
of a pH-meter immersed in the reaction mixture and adding concentrated 
aqueous NaOH when needed. Then the mixture was made to pH 7 with 
1M hydrochloric acid, and clarified by filtration through filter paper under 
vacuum. Next it was purified by dialysis (Spectra/Por®, cut-off 3500, 
Spectrum Laboratories Inc., Rancho Dominguez, CA, USA) under sink 
conditions. The dialysis was continued until no chloride was found in the 
external phase, then the internal solution was lyophilized to obtain the 
purified product. Each chitosan derivative is coded N+-Ch-x, where x is a 
figure indicating the pH at which the synthesis was carried out. The 
property of N+-Ch-7 or N+-Ch-8 to dissolve in neutral aqueous environment 
was investigated by progressively adding the polymer portionwise to 
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phosphate buffer pH 7.4 under stirring, and observing the aspect of the 
resulting mixture. 
 
II.2.3 NMR studies 
The effect of the synthesis conditions on polymer MW was studied 
by NMR using the Diffusion Ordered SpectroscopY (DOSY) technique. 
This allows measurement of diffusion coefficients (D) in solution, which 
depend on molecular hydrodynamic radius (RH), and hence, on molecular 
size, according to the following Stokes–Einstein equation [48]: 
 
 
where k is the Boltzmann constant, T is the absolute temperature, and η is 
the solvent viscosity.  
On this basis, also the diffusion coefficients of polymeric materials 
have been correlated with their molecular weights [44]. 1H NMR 
measurements were performed on a NMR spectrometer operating at 600 
MHz. The temperature was controlled to ± 0.1°C. DOSY experiments were 
carried out by using a stimulated echo sequence with self-compensating 
gradient schemes, a spectral width of 5000 Hz and 32K data points. 
Typically, a value of 700ms was used for ∆, 1.5ms for δ, and g was varied 
in 20 steps (four transients each) to obtain the better decrease in the 
resonance intensity at the largest gradient amplitudes. The baselines of all 
arrayed spectra were corrected prior to data processing. After data 
acquisition, each FID was apodized with 1.0 Hz line broadening and 
Fourier transformed. The data were processed with the DOSY macro 
(involving the determination of the resonance heights of all the signals 
above a pre-established threshold and the fitting of the decay curve for 
each resonance to a Gaussian function) to obtain pseudo two-dimensional 
spectra with NMR chemical shifts along one axis and calculated diffusion 
coefficients along the other. 
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II.2.4 Permeation experiments 
For permeation studies, the intestinal mucosa was excised from 
non-fasting male Wistar rats weighing 250–300 g. After sacrificing the rats, 
the first 20cm of jejunum were immediately removed. The excised intestine 
was cut into strips of 1.5 cm, rinsed free of luminal contents and mounted 
in Ussing type chambers (0.78cm2 exposed surface area) without stripping 
off the underlying muscle layer. The pre-thermostated donor medium, 
containing 250 mM NaCl, 2.6 mM MgSO4, 10 mM KCl, 40 mM glucose 
and 50 mM NaHCO3 buffered with 50 mM Hepes (N-[2-hydroxyethyl] 
piperazine-NI-[2-ethanesulfonic acid]) pH 6.8 was added to the apical side 
and the same salt composition buffered with 40 mM Hepes pH 7.4 was 
added to the basolateral side. In order to ensure oxygenation and 
agitation, a mixture of 95% O2 and 5% CO2 was bubbled through each 
compartment. The Ussing chambers were then placed in a water bath at 
37 °C. After a 20-min equilibration period, a solution of NaFlu (0.2%, w/v), 
or FD4 (0.1, 0.2 or 0.5%, w/v), or Rh-123 (0.001%, w/v) in the donor 
medium was added to the apical chambers. The apical to basolateral 
transport of the drug models was investigated in the absence or presence 
of 0.5% (w/v) of the polymer under test in the donor (TMC, N+-Ch-7 or N+ 
Ch-8). At 30-min intervals over 180 min, 100µl samples were withdrawn 
from the acceptor chambers and replaced by the same volume of fresh 
medium. The amount of permeated drug model was determined by HPLC, 
as already described [26, 55]. 
 
II.2.5 Measurement of drug–polymer interactions 
A previously described method, based on the dynamic dialysis 
technique [20], was used as described in Section I.2.6 to determine the 
drug-polymer interactions in the donor phase of the permeation 
experiments referred to in the preceding section. Drug flux through a 
porous cellulose membrane (molecular weight cut-off, 3500 Da, with NaFlu 
or Rh-123, or 10000-12000 Da, with FD4) under quasi-steady state 
conditions was measured in the presence or absence of the polymer in the 
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donor phase. The polymer and initial drug concentrations in the donor 
were equal to those used in the ex vivo permeation experiments, referred 
to in the preceding Section. The receptor was analysed for the drug by 
HPLC, as already described [26, 55].  
The regression for the fitting of dialysis data, expressed as drug 
concentration in the donor vs. time, to 1st order kinetics was always 
significant (r2≥ 0.97, n≥ 8). This allowed calculation of the fraction of free, 
non-interacting drug, fF, as described in Section I.2.6. 
Permeation data were treated as previously described in Section 
I.2.7. 
 
II.2.6 Test of viability of epithelial cells 
Epithelial cell viability following contact of intestinal mucosa with 
N+-Ch-7 or N+-Ch-8 was checked by the trypan blue test [45, 53]. 
After the permeation experiments, the donor medium was replaced by 1ml 
trypan blue die and the mucosa was incubated for 30 min. Microscopy 
demonstrated that the mucus was still present. No blue colour was 
detectable within the cells, thus testifying to their viability. These 
observations were in agreement with the results of viability studies 
previously published by others [45, 53]. 
 
II.3 Results and discussion 
 
II.3.1 Control of the aminoalkylation reaction 
We have verified that the synthesis reaction of the N+-Ch 
conjugates, if performed as in our previous work [31, 55], has an 
unsatisfactory reproducibility of the structural parameters DS and n. This 
would imply a difficulty in predetermining these values and, consequently, 
the permeability-enhancing properties of the polymer. It was thought that 
this was due to the lack of a strict control of the reaction mixture pH. 
Therefore, in the present work such a pH has been controlled strictly at 5, 
6, 7, 8 or 9 over the reaction time. The characteristics of the derivatives 
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obtained, determined by NMR as described in the previous paper [31], are 
reported in Table II.1. It was observed that at pH 5 the reaction did not 
occur, at pH 6 it was not reproducible, at pH 7 or higher the reaction was 
reproducible. In particular, as the pH was increased from 7 to 8 the DS 
value increased while the n value decreased. A pH increase from 8 to 9 
exerted no further effect. Thus, the control of the reaction pH succeeded in 
making both the reaction reproducible and the structural parameters 
modulatable. When N+-Ch-7 or N+-Ch-8 was progressively added to 
phosphate buffer pH 7.4 a clear solution was initially obtained. This 
became a clear gel, which blocked the stirring, when the polymer 
concentration reached 0.4–0.5 g/ml. At thermodynamic equilibrium the 
system always appeared to be composed of a single, clear phase. Then it 
can be stated that both derivatives are freely water-soluble in neutral 
environment. As stated in the Introduction section, the MW of polymer 
could influence its enhancing effect on drug transport across the intestinal 
epithelium [51]. This prompts the question whether the synthesis 
conditions could cause some fragmentation of the Ch chain. In principle, 
no important fragmentation was expected in the cases where a pH close 
to neutrality (e.g., 7 or 8) was maintained throughout the synthesis. 
Nevertheless, NMR studies using the DOSY technique were carried out to 
confirm this assumption. The starting Ch is characterized by a high MW, 
and hence, by a diffusion coefficient in the limit region of determination by 
DOSY technique. Nevertheless, fragmentation should result in a 
significant increase of diffusion coefficient. In fact, it appears from the 
DOSY maps presented in Fig. II.1. that the diffusion coefficients of the Ch 
derivatives N+-Ch-7 and N+-Ch-8, not significantly different from each 
other, were not increased with respect to the parent Ch. This indicates that 
in neither case did the synthesis conditions produce any important chain 
fragmentation. 
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II.3.2 Permeation experiments 
The excised rat jejunum was chosen among the known intestinal 
epithelium models for the permeability enhancement studies because its 
tight junctions are similar in tightness and number to those of the human 
jejunum [49] and because the Ch derivatives under study are expected to 
act by modulating intercellular tight junctions [55]. A TMC with a DQ of 
46% was chosen as a reference to evaluate the effectiveness of the 
present N+-Ch conjugates because it was reported that TMC with 
intermediate DQ is most effective in enhancing drug permeability across 
mucosal epithelia [20,30,47). 
 
II.3.2.1 Data for NaFlu 
Data on NaFlu permeation are listed in Table II.2. As in the case of 
the Ch derivatives studied in our previous work [55], also the present ones 
showed a significant binding of the NaFlu molecules, indicated by the 
relevant fF values. Therefore, the Papp values, calculated by Eq. I.2., were 
significantly enhanced by the polymers over the control, even though the 
flux values were not. In fact, with each polymer the mean flux was lower 
than the control value. These findings support the consideration at the 
basis of Eq. I.2., i.e., drug–polymer binding counteracted the enhancing 
effect of polymer on transmembrane flux by limiting the fraction of free 
drug. On the other hand, the possible hypothesis that the polymer might 
mediate transepithelial drug transport by concurrently interacting with the 
drug and with the epithelium is not supported by the flux values, in no case 
higher than the control value. As appears from Table II.2., the Papp values 
for N+-Ch-7 and N+-Ch-8 are not significantly different, whereas the value 
for N+-Ch-7 is significantly higher than that for TMC. No appreciable lag 
time before attainment of steady-state flux was ever noticed with NaFlu. 
 
II.3.2.2 Data for FD4 
The ability of N+-Ch conjugates to enhance the intestinal epithelium 
permeability to hydrophilic macromolecules was compared with that of 
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TMC using FD4 (MW 4400 Da), an extensively used marker of the 
paracellular route. As appears in Table II.3., the Papp of this 
macromolecule, in the absence of enhancers, is much lower than that 
seen in Table II.2. for enhancer-free NaFlu, as expected considering that 
both were transported across the paracellular route and that the molecular 
size of FD4 is much larger than that of NaFlu. As in the case of NaFlu, 
discussed above, the FD4 molecule was significantly bound to the 
polymers, so the free fraction was used to calculate the relevant Papp 
values. All polymers resulted effective permeability enhancers, N+-Ch-8 
being significantly more effective than N+-Ch-7 or TMC. Because FD4 is 
supposed to travel the paracellular route, the hypothesis that N+-Ch 
conjugates act by loosening the epithelial tight junctions is sound. Such an 
effect is significantly stronger with the conjugate having higher DS and 
lower n value. In principle, the significant FD4-polymer binding, testified by 
the fF values in Table II.3., in addition to depressing FD4 transmembrane 
flux could hamper the polymer action to decrease the epithelium barrier 
properties. If this were the case, increasing FD4 concentrations at 
constant N+-Ch concentration would decrease the Papp value. 
Unexpectedly, the data in Table II.4. indicate that the opposite is true, i.e., 
the Papp is significantly higher with the highest than with the lowest FD4 
concentration. These results could be explained by admitting that the 
permeant fraction interacting with the polymer is not completely 
impermeable, possibly due to a parallel penetration mechanism different 
from passive permeation. 
 
II.3.2.3 Data for Rh-123 
In Table II.5., data are listed on Rh-123 permeation across the 
excised rat jejunum. It is noteworthy that the apparent permeability value 
for the control is three orders of magnitude higher than that for the 
respective control value for Rh-123 permeation across excised porcine 
buccal epithelium, reported previously [31]. N+-Ch-7 was the only 
conjugate to enhance the Papp significantly with respect to the control, 
 35
 
 
although its effect on the cumulative transport is not significant, due to a 
comparatively high lag time. It should be considered, however, that 
possible enhancing effects on epithelial permeability by the other polymers 
could be masked by the muscle layer underlying the epithelial membrane. 
Such a layer, indeed, could control the permeation rate of such a lipophilic 
molecule as Rh-123. The conjugate N+-Ch-7, having lower DS and higher 
n value, exerted a stronger enhancing effect on the permeability of Rh-
123, as can be seen in Table II.5. According to Sakai et al. (1997) [50], 
Rh-123 crosses the intestinal epithelium by the transcellular, in addition to 
the paracellular route. This suggests that the effect of N+-Ch-7 on Papp is 
apparently stronger than that of N+-Ch-8 because of more ability of the 
former to act on the transcellular route, e.g., by perturbing the order of the 
plasma membrane lipids. As a hypothesis, such an ability could be due to 
the higher n value for the pendant chains of N+-Ch-7, which would elicit a 
stronger interaction with the epithelial cell membrane. TMC was apparently 
inactive, perhaps because it was not endowed with a similar interactive 
strength. Considering that the positive charge per unit repeating unit of N+-
Ch-7 and N+-Ch-8 is similar, the hypothesis can be advanced that the 
pendant chain of adjacent quaternary ammonium groups, whether longer 
or shorter, determines the ability of N+-Ch conjugates to enhance the 
transcellular rather than the paracellular route or vice versa. The fF values 
in Table II.5. testify to an absence of Rh-123 binding to the polymers. The 
L value for N+-Ch-7 is significantly higher than the values for the control 
and the apparently inactive polymers, indicating that some time was 
needed for the enhancing effect to be exerted. 
 
II.4 Conclusions 
The structural parameters, DS and n, of the N+-Ch conjugates can 
be controlled by strictly controlling the pH at which the N+-Ch synthesis 
from Ch is carried out. The pH values of 7 and 8 have reproducibly yielded 
the more significant derivatives, N+-Ch-7 and N+-Ch-8. The present ex vivo 
procedure used to determine the Papp of the excised intestinal wall shows 
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intrinsic limits, e.g., such a membrane comprises both mucosal epithelium 
and underlying muscle tissue. Therefore, the obtained Papp values can 
only be used for comparative purposes. In this light, it can be concluded, 
on the basis of the present results, that the Ch derivatives N+-Ch-7 and 
N+-Ch-8 are more effective absorption enhancers than the TMC specimen 
used as a reference in the present study. Of the excised intestinal 
membrane structures, the mucosal epithelium was rate-controlling enough 
to discriminate between different polymers as concerns their permeability-
enhancing properties. This can be interpreted as a sign of preservation of 
epithelium integrity, as also demonstrated by the trypan blue test. The 
permeation data have prompted the hypothesis that the structural 
parameters, DS and n, for a conjugate may be correlated with the 
conjugate ability to promote drug penetration across the excised intestinal 
membrane via the transcellular or the paracellular route. Thus, the 
penetration of the lipophilic Rh-123 has been enhanced by N+-Ch-7, 
having lower DS and higher n, more than by N+-Ch-8, which has higher 
DS and lower n. The opposite is true with the hydrophilic macromolecular 
FD4, for which N+-Ch-8 has exerted a stronger enhancement than N+-Ch-
7. Only in the case of Rh-123, which showed no appreciable interaction 
with the polymers, did the Papp enhancement result in a significant 
enhancement of permeation flux with respect to the control. On the other 
hand, this was not the case of the negatively charged NaFlu or FD4, 
because a significant binding of these permeants by the polycationic N+-
Ch conjugates would limit the respective fluxes. Hence, a significant 
enhancement of paracellular absorption of hydrophilic drugs of either low 
or high molecular weight by the present chitosan derivatives is expected 
for drugs that do not interact significantly with the polymer at the 
absorption site. As for the mode of application of these polymeric 
enhancers to the intestinal mucosa, it should be considered that they are 
readily soluble in the fluids of the intestinal lumen, so it would be 
appropriate, e.g., to introduce them as solid water soluble excipients into 
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enteric-coated tablets. The viability tests have shown that these excipients 
are safe on the intestinal mucus and epithelial cells. 
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TABLES 
 
Table II.1. – Effect of the reaction pH on the structural characteristics of the N+-Ch 
conjugates 
Polymer code Reaction pH DSa (%) nb Notes 
N+-Ch-5 5 - - The reaction does not occur 
N+-Ch-6 6 - - The reaction is not reproducible 
N+-Ch-7 7 40.6 ± 1.3 3.0 ± 0.2 The reaction is reproducible 
N+-Ch-8 8 59.2 ± 4.5 1.7 ± 0.1 The reaction is reproducible 
N+-Ch-9 9 52.5 ± 8.0 1.4 ± 0.1 The product is not significantly 
different from N+-Ch-8 
aDegree of substitution, determined by NMR analysis. Mean ± S.D. of 6 batches. 
bNumber of quaternary ammonium groups in pendant chains, determined by NMR 
analysis.  
Mean ± S.D. of 6 batches. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 39
 
 
Table II.2. – Data on NaFlu permeation across excised rat jejunal epithelium from Ringer 
buffer pH 6.8 containing 0.2% (w/v) NaFlu and 0.5% (w/v) of different Ch derivatives. 
Polymer  Flux (µg cm-2h-1) fFa Pappb (x105 cm s-1) ERc T3h (µg cm-2)d 
Control 113.4 ± 15.7 - 1.57 ± 0.20 - 314.6 ± 21.5 
TMC 98.0 ± 7.4 0.70 1.95 ± 0.15* 1.24 265.4 ± 10.3 
N+-Ch-7 101.1 ± 19.5 0.49 2.89 ± 0.56* 1.84 267.5 ± 20.4 
N+-Ch-8 86.6 ± 11.5 0.58 2.09 ± 0.28* 1.33 246.2 ± 13.4 
Means ± S.D. of at least 6 runs. The data marked by (*) are significantly different from 
the respective controls (P<0.05). 
a
  
Fraction
 
of free permeant. 
b
 Apparent permeability. 
c
 Enhancement ratio. 
d
 Cumulative transport over the whole time of experiment (3h). 
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Table II.3. – Data on FD4 permeation across excised rat jejunal epithelium from Ringer 
buffer pH 6.8 containing 0.2% (w/v) FD4 and 0.5% (w/v) of different Ch derivatives 
Polymer Flux  
(µg cm-2h-1) 
L (h)a fFb Pappc  
(x106 cm s-1) 
ERd T3h  
(µg cm-2)e 
Control 21.6 ± 5.30 0.45 ± 0.10  - 3.00 ± 0.74  - 55.1 ± 5.4 
TMC 20.4 ± 1.41 0.68 ± 0.11 0.66 4.29 ± 0.30* 1.43 48.0 ± 3.4 
N+-Ch-7 20.2 ± 2.95 0.49 ± 0.14 0.62 4.52 ± 0.66* 1.51 52.3 ± 3.7 
N+-Ch-8 29.1 ± 4.49 0.99 ± 0.17 0.63 6.41 ± 0.99* 2.14 58.5 ± 6.6 
Means ± S.D. of at least 6 runs. The data marked by (*) are significantly different from 
the respective controls (P<0.05). 
a
 Lag time. 
b
 
Fraction
 
of free permeant. 
c
 Apparent permeability. 
d
 Enhancement ratio. 
e
 Cumulative transport over the whole time of experiment (3h). 
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Table II.4. – Data on FD4 permeation across excised rat jejunal epithelium from Ringer 
buffer pH 6.8 containing 0.2% (w/v) FD4 and 0.5% (w/v) of different Ch derivatives. 
Donor 
solution 
FD4  
(%, w/v) 
Flux  
(µg cm-2h-1) 
L (h)a fFb Pappc  
(x106 cm s-1) 
ERd 
Control 0.1 14.1 ± 2.0 0.37± 0.03   -     3.92 ± 0.55 - 
Test 0.1 14.8 ± 2.8 0.39± 0.22 0.59 6.96 ± 0.13* 1.77 
Control 0.2 21.6 ± 5.3 0.45± 0.10 - 3.00 ± 0.74 - 
Test 0.2 29.1 ± 4.5 0.99±0.17* 0.63 6.41 ± 0.99* 2.14 
Control 0.5 80.4 ± 14.8 0.36±0.13 - 4.46 ± 0.82 - 
Test 0.5 112.1 ± 17.4* 0.67±0.19* 0.56 11.12 ± 2.72* 2.49 
Means ± S.D. of at least 6 runs. The data marked by (*) are significantly different from 
the respective controls (P<0.05). 
a
 Lag time. 
b
 
Fraction
 
of free permeant. 
c
 Apparent permeability. 
d
 Enhancement ratio. 
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Table II.5. - Data on Rh-123 permeation across excised rat jejunal epithelium from 
Ringer buffer pH 6.8 containing 10 µg/ml Rh-123 and 0.5% (w/v) of different Ch 
derivatives 
Polymer Flux 
 (µg cm-2h-1) 
L (h)a fFb Pappc  
(x105 cm s-1) 
ERd T3h  
(µg cm-2)e 
Control 0.36 ± 0.06 0.73 ± 0.51  - 1.00 ± 0.16  - 0.85 ± 0.16 
TMC 0.35 ± 0.08 0.52 ± 0.31 1 0.97 ± 0.22 - 0.88 ± 0.09 
N+-Ch-7 0.49 ± 0.03* 1.21 ± 0.13* 1 1.37 ± 0.08* 1.37 0.92 ± 0.05 
N+-Ch-8 0.40 ± 0.02 0.81 ± 0.55 1 1.11 ± 0.06 - 0.84 ± 0.11 
Means ± S.D. of at least 6 runs. The data marked by (*) are significantly different from 
the respective controls (P<0.05). 
a
 Lag time. 
b
 
Fraction
 
of free permeant. 
c
 Apparent permeability. 
d
 Enhancement ratio. 
e
 Cumulative transport over the whole time of experiment (3h). 
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FIGURES 
 
 
Figure II.1. - DOSY maps (600 MHz, D2O, 80°C) for ChHCl (a), N+-Ch-8 (b)  
and N+-Ch-7 (c). 
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SECTION III - A Novel Polyelectrolyte Complex (PEC) 
Hydrogel for Controlled Drug Delivery to the Distal 
Intestine 
 
III.1 Introduction 
Hydrogels are defined as macromolecular networks swollen in 
water or biological fluids [56]. The considerable amount of water they are 
able to absorb makes them similar to living tissues, therefore, they are 
biocompatible and suitable for biomedical and pharmaceutical applications 
[57]. The networks of chemical hydrogels are formed by irreversible, 
covalent crosslinking. However, free unreacted covalent crosslinkers are 
potentially toxic, therefore alternative types of networks, formed by direct 
physical interactions between polymer chains without the addition of 
crosslinkers, have been developed [58]. A component of these hydrogel 
types is chitosan, a polycationic biocompatible polymer generally 
produced at low cost by alkaline deacetylation of chitin, which is the main 
component of the exoskeleton of crustaceans [59]. These hydrogels were 
formed by chitosan complexation with an oppositely charged 
polyelectrolyte. The electrostatic attraction between the positively charged 
amino groups of chitosan and the negatively charged groups of the other 
polyelectrolyte led to the formation of the polyelectrolyte complex (PEC). 
PECs have been used to prepare drug delivery systems. Their essential 
properties have been reviewed by Berger et al. [58]. In order to form a 
PEC both component polyelectrolytes must be in the ionized form. 
Chitosan is in the unionized amine form at the neutral/alkaline pH of 
physiological application sites of many drug delivery systems, while the 
anionic polyelectrolyte is in the ionized form. In these conditions no stable 
PEC can be formed. Therefore it could be convenient to use, as the 
polycation, the quaternized chitosan derivative N-trimethyl chitosan (TMC), 
which is ionized irrespective of pH. Although TMC is not commercially 
available as yet, vast literature information is available on its synthesis 
from chitosan, purification, biopharmaceutical properties, safety (see e.g., 
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Ref. 60). In fact, TMC is considered as safe, biocompatible and 
biodegradable as the parent chitosan. A biocompatible biodegradable and 
safe polyanion could be obtained by grafting carboxymethyl groups onto 
the chitosan backbone, to yield N-carboxymethyl chitosan (CMCh) [61]. In 
the present work microcapsules (MCPS) entrapping controlled amounts of 
fluorescein isothiocyanate dextran, MW 4400 Da (FD4), a model of water-
soluble macromolecular drugs, or of fine particles of the barely soluble 
anti-inflammatory dexamethasone (DMS), into a PEC hydrogel at 
physiological pH have been prepared by directing a fine spray of a CMCh 
solution containing dissolved FD4 or dispersed DMS into a TMC solution. 
The mechanism of MCPS formation, the encapsulation efficiency and the 
in vitro drug release from MCPS to simulated intestinal environment have 
been investigated. PEC MCPS have been compressed into monolithic 
matrices, these have been enteric coated with Eudragit S100, and drug 
release from the coated systems to simulated GI fluids has been studied in 
vitro. The aim has been the design of a biocompatible and biodegradable 
system for the controlled and complete release of either macromolecular 
drugs, such as peptides and proteins, or barely water-soluble drugs, such 
as DMS, to the distal intestine. After dissolution of the enteric coating and 
swelling of the hydrogel, the release of the water-soluble macromolecular 
FD4 is expected to be comparatively slow due to its intrinsically low 
diffusion coefficient in the hydrogel, while the poor solubility of DMS 
should be responsible for a slow dissolution of this drug from the hydrogel. 
On the other hand, the high solubility of FD4 and the high specific surface 
area and diffusivity of DMS in the aqueous phase of the hydrogel should 
allow the release of these drug models from the hydrogel being complete 
during transit across the intestinal tract. 
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III.2 Materials and Methods 
 
III.2.1 Materials 
Dexamethasone (DMS), fluorescein isothiocyanate dextran, MW 
4400 Da (FD4), chitosan from crab shells (ChC, minimum 85% 
deacetylated, viscometric MW 900 KDa) were purchased from Sigma. 
Chitosan from shrimps (ChS, minimum 90% deacetylated, viscometric MW 
590 KDa) (Chito-Clear FG90, Primex, Drammen, Norway) was kindly 
gifted by Giusto Faravelli, Milan, Italy. Eudragit S100 and triethyl citrate 
were kindly gifted by Rofarma Italia, Milan, Italy. N-trimethyl chitosan 
(TMC) was synthesized from ChS as described by Di Colo et al. [62]. N-
carboxymethyl chitosan (CMCh) was synthesized from ChC as described 
by Di Colo et al. [63]. DMS (water solubility, 0.1 mg/ml [64]) was obtained 
as microparticles (<1.3 µm) by spray-drying a 0.09 mg/ml solution (Mini 
Spray Drier BÜCHI B-191, inlet and outlet temperature, 150°C and 60°C, 
respectively; spray nozzle, 0.7 mm; feed flow, 8 ml/min). 
 
III.2.2 Preparation and Characterization of PEC Microcapsule (MCPS) 
PEC MCPS containing FD4 in solution or DMS microparticles in 
dispersion were obtained by directing a spray of a 1% aqueous CMCh 
solution containing 1% FD4 or 0.1% DMS microparticles (two-fluid nozzle, 
diameter 0.4 mm; air pressure, 1 bar; spray rate 2 ml/min) into a 2% TMC 
solution. The volume of the TMC solution was double that of the CMCh 
solution. The MCPS were collected by centrifugation (MLW T 52.2; 3000 
rpm, 5 min), repeatedly (two-three times) washed with water, and the 
sediment lyophilized (Virtis, Advantage-53; freezing step: -35°C in 180 
min; drying cycle steps: 1) -30°C, 360 min; 2) -10°C, 360 min; 3) 10°C, 
240 min; 4) 25°C, 180 min). Non-medicated PEC MCPS were also 
prepared. The output of each process of MCPS preparation was 
expressed as grams of lyophilized material obtained from 1g of CMCh. 
The ability of the different processes to produce MCPS from plain CMCh 
was compared via the respective output values. 
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III.2.3 MCPS Size 
Immediately after preparation of the MCPS dispersion, this was 
observed on an optical microscope equipped with a stage micrometer. 
 
III.2.4 MCPS Morphology 
The shape and surface morphology of lyophilized MCPS, either 
drug loaded or drug free, were examined by scanning electron microscopy 
(SEM) (Jeol JSM 5600LV) after coating with gold by sputter-coating 
(Edwards S150B). 
 
III.2.5 Solid State NMR Measurements 
All the 1H and 13C high-resolution solid-state NMR experiments 
were performed on CMCh, TMC and lyophilized MCPS using a Varian 
InfinityPlus 400 double channel spectrometer operating at the 1H 
frequency of 399.89 MHz and 13C frequency of 100.56 MHz, equipped with 
a CP-MAS probe for rotors with an outer diameter of 3.2 mm. Both 13C and 
1H 90° pulses were 2.1 µs. The carbon spectra were acquired under Magic 
Angle Spinning (MAS) and high-power decoupling conditions, using the 
Cross Polarization (CP) pulse sequence and a spinning rate of 6 kHz: the 
optimized contact time and relaxation delay were 0.5 ms and 5 s for both 
CMCh and TMC, and 0.2 ms and 10 s for the lyophilized MCPS, 
respectively. The 13C Direct Excitation (DE) spectra for all samples were 
acquired using a depth pulse sequence for background suppression [65] 
at the spinning rate of 6 kHz with a relaxation delay of 2 s. 1H low-
resolution solid-state NMR experiments were performed at the Larmor 
frequency of 25 MHz on a singlechannel Varian XL-100 spectrometer 
interfaced with a DSNMR Stelar acquisition system and equipped with a 5 
mm probehead. In all experiments the Free Induction Decays (FID) were 
acquired in on-resonance conditions following a solid-echo pulse 
sequence to avoid the dead time effect; the 90° pulse length and the echo 
delay were 2.7 and 13 µs, respectively. 
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III.2.6 Drug Release Kinetics, Drug Content, and Entrapment 
Efficiency 
Medicated MCPS (about 5 mg, accurately weighed) were added to 
a screw-capped vial containing 25 ml of phosphate buffer pH 7.4, 0.13 M. 
The vial was fixed radially to a rotating wheel (26 rpm) kept in an 
atmosphere thermostated at 37°C. Sink conditions were always ensured. 
At appropriate time intervals, 1-ml aliquots were withdrawn, centrifuged, 
and the surnatant was analyzed for the drug by HPLC. To determine the 
drug content in MCPS, these were completely depleted of drug. To this 
purpose the release experiments were protracted for 24 h, then the 
dissolution medium was analysed for the drug, and the absence of any 
further drug release was verified. Depletion was generally complete within 
24 h. The entrapment efficiency was expressed as the ratio of the drug 
mass contained in the lyophilized MCPS to the total drug mass sprayed 
into the TMC solution. The latter was calculated knowing the drug 
concentration in the sprayed CMCh solution and the total volume of this 
solution. 
 
III.2.7 HPLC Analysis 
The HPLC techniques described by Sandri et al. [26] and by 
Zambito et al. [27] were used for the analysis of FD4 and DMS, 
respectively. 
 
III.2.7.1 FD4 
The apparatus (Perkin-Elmer) consisted of Series 200 pump, 20 µl 
Rheodyne injector, Series 200 fluorescence detector and Turbochrom 
Navigator HPLC software for data integration. A C18 column Hyperbond 
C18 10 µm, 300 mm x 3.9 mm, was used. The mobile phase consisted of 
2.5 mM KH2PO4 pH 5.0 (91.5%) and acetonitrile (8.5%). The flow rate was 
1 ml/min. The detection wavelengths were: excitation λ = 490 nm and 
emission λ = 515 nm. A calibration curve was constructed using FD4 
 50
 
 
concentrations ranging from 0.5 to 20 µg ml-1. Linearity was observed in 
the above concentration range (r2 > 0.99). 
 
III.2.7.2 DMS 
The apparatus described above was used, with UV detection 
(Perkin Elmer LC 290) set at 241 nm. A Spheri-5 RP18 250mm x 4.6 mm 5 
µm column was used. The mobile phase (flow rate 1.0 ml/min) was water–
acetonitrile–tetrahydrofuran (64:35:1). A calibration curve was constructed 
using DMS concentrations ranging from 0.5 to 20 µg ml-1. Linearity was 
observed in the above concentration range (r2 > 0.99). 
 
III.2.8 Drug Release from Monolithic Matrices Prepared from PEC 
MCPS 
 
III.2.8.1 Preparation of Matrices 
The lyophilized MCPS, either drug containing or drug free, were 
directly compressed into circular flat-faced monolithic matrices of 20 mg 
weight and 6 mm diameter. For compaction, a force of 1000 kg was 
applied for 15 s by a hydraulic press (Perkin-Elmer). 
 
III.2.8.2 Swelling Kinetics of Matrices 
At time zero, the matrices were immersed in water at 37°C. At 
appropriate intervals they were withdrawn and rapidly blotted dry and 
weighed (10-5 g). The swelling degree was expressed as ratio of swollen to 
initial dry weights. The swelling kinetics were measured for 24 h. 
 
III.2.8.3 Enteric Coating of Matrices 
Matrices were enteric coated by a spraying technique. The matrices 
were placed on a rotating plate (37 rpm) and sprayed on the upper face 
and on the edge with a methanolic solution of 5% Eudragit S100 and 0.5% 
triethyl citrate. The two-fluid spray nozzle (diameter, 0.4 mm; air pressure, 
1 bar; spray rate, 7.5 ml/min) was kept in a fixed position, so that the spray 
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wetted a limited portion of the rotating plate surface, centered at a 3.5-cm 
distance from the rotation axis. The matrices were placed on the plate in 
circle, at this distance from the axis, so that each matrix was wetted by the 
spray for about 0.4 s for every rotation of the plate. Every 4th rotation, the 
spraying was interrupted, the coating was dried by an air stream at room 
temperature, the matrices were turned upside-down and an equal coating 
was applied on the other face. The process was stopped when the weight 
of the coating reached 5±0.2 mg. 
 
III.2.8.4 Composition of Simulated GI Fluids 
Simulated gastric fluid (SGF) consisted of HCl 0.04 M, pH 1.2, 
made isotonic with NaCl; simulated jejunal fluid (SJF) was phosphate 
buffer pH 6.8, 0.13 M, made isotonic with NaCl; simulated ileal fluid (SIF) 
was phosphate buffer pH 7.4, 0.13 M, isotonic. 
 
III.2.8.5 Preparation of Simulated Ascending Colon Environment 
(SACE) 
A) In the Absence of Cecal Contents 
A phosphate buffer pH 6.0 containing 0.073 g/l CaCl2, 0.087 g/l 
MgCl2, 0.450 g/l KCl, 28.126 g/l NaH2PO4, and 4.992 g/l Na2HPO4 (code, 
SACE/PB) was used.  
For some experiments an acetate buffer pH 6.0, containing 14.96 
g/l CH3COONa 3H2O, 0.075 g/l NaCl, 340 µl/l glacial CH3COOH (code, 
SACE/AB) was used. 
 
B) In the Presence of Cecal Contents 
About 3 g of cecal contents, taken from a Wistar rat, were diluted 
1:3 with SACE/PB, the dispersion was immediately centrifuged (3000 rpm, 
10 min) and the surnatant ultracentrifuged (39000 rpm, 15°C, 30 min). The 
surnatant from the ultracentrifugation was saturated with CO2 to attain a 
constant pH of 5.6 (code, SACE/PB/CC). 
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III.2.8.6 Measurement of Release Kinetics 
The apparatus was the same as that described above for the 
release experiments with the MCPS. Each matrix, containing FD4 or DMS, 
was agitated at 37°C in 5 ml (case of FD4) or 25 ml (case of DMS) of 
dissolution medium, simulating the environment of a specific region of the 
GI tract, for a specified time period, after which the medium was replaced 
by a different one to simulate matrix transit across different GI regions. 
Sink conditions were always ensured. At appropriate intervals, 100-µl 
(case of FD4) or 20-ml (case of DMS) samples of each dissolution medium 
were withdrawn and replaced with equal volumes of fresh pre-
thermostated medium. A superficial matrix disintegration was observed 
during elution with the buffers having pH≤6 (SACE/PB, SACE/AB, 
SACE/PB/CC). In these cases the vial was subjected to centrifugation 
(3000 rpm, 2 min) before sampling. Samples were analyzed for FD4 and 
DMS by the respective above-mentioned HPLC techniques, and the 
cumulative drug fraction released was calculated. The uncoated matrices 
were generally eluted with SIF for 2 h, followed by SACE/PB, or SACE/AB, 
or SACE/ PB/CC, for the successive 4 h. The enteric-coated matrices 
were eluted in sequence with SGF (2 h), SJF (2 h), SIF (2 h), and 
SACE/PB (4 h). 
 
III.2.8.7 Release Data Treatment 
The release data were analyzed, up to 50-60% release, by the 
following phenomenological equation, known as Peppas equation [66]: 
F = Kt n                                                                                               Eq. III.1 
where F is the dose fraction released in time t; K is a rate parameter; and 
the time exponent, n, measures the curvature of the release profile, hence, 
is related to the release mechanism. Eq. III.1 is applicable up to a released 
fraction of 60%. 
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III.3 Results and Discussion 
 
III.3.1 Preparation and Characterization of PEC MCPS 
Optical microscopy was used to measure the size interval of 
suspended MCPS, before their collection.  
Spherical particles in the size ranges listed in Table III.1. were made out.
The drug-free ones and those prepared with a solution of FD4 appeared 
clear, whereas those prepared with a dispersion of DMS appeared 
opaque, indicating the entrapment of DMS microparticles (size, <1.3 µm) 
within the microspheres (size, 20-100 µm). This analysis, however, could 
not make clear the structure of microspheres, i. e., these could be either 
monolithic particles or MCPS. In order to clarify this point, a CMCh solution 
was dripped into a solution of an excess TMC: the formation of 
macroscopic capsules of the same size as the CMCh solution drops was 
observed, as shown in Fig. III.1. 
It was also observed that when the opposite was done, namely, a TMC 
solution was dripped into a solution of CMCh in excess, small particles of 
irregular shape were formed instead of macroscopic capsules. Probably, 
in the former instance the formation of the CMCh-TMC complex at the 
interface between the drops of CMCh solution and the external TMC 
solution was faster than the dispersion of the drops into the solution bulk. 
The PEC would form a spherical wall at the interface, which would prevent 
further mixing of polymers. The dispersion of the drops was comparatively 
slow because of the comparatively high viscosity of the CMCh solution. On 
the other hand, when the TMC solution, having a comparatively low 
viscosity, was dripped into the CMCh solution, the drops would disperse 
more rapidly, therefore small and irregular PEC particles were formed. 
These considerations are believed to apply as well to the microdrops of 
CMCh solution sprayed into the TMC solution, hence the microparticles, 
the properties of which are listed in Table III.1. should in fact be MCPS 
entrapping a solution of FD4 or a dispersion of DMS. The low SD values 
appearing in Table III.1. testify to a good reproducibility of the preparation 
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procedure. The output of such a procedure for the drug-free and the FD4 
MCPS was virtually equal, whereas it was significantly lower for the DMS 
MCPS. Apparently, the conversion of the microdrops of the DMS 
dispersion into MCPS was comparatively difficult. Indeed, for the PEC wall 
to be formed at the microdrop surface CMCh had to diffuse from the inside 
of the drop to the drop surface. Such a diffusion could well be hindered by 
the DMS microparticles dispersed in the microdrops, so less TMC was 
adsorbed on the drop surface in the case of DMS than in that of FD4 or of 
the drug-free microdrops. On the other hand, the entrapment efficiency 
(EE) was much higher with the DMS dispersion than with the FD4 solution. 
In fact, in the latter case the EE value seen in Table III.1. is exceedingly 
low, which is indicative of a pronounced tendency of the FD4 molecules to 
escape from MCPS during their formation. With DMS the EE value is 
much higher, possibly because the solution outside the MCPS soon 
became saturated with this barely soluble drug, thus limiting its diffusion-
driven leakage. 
The SEM micrograph in Fig.III.2. shows the collapsed PEC shell of a DMS 
MCPS from the inside of which water has been removed by lyophilization. 
None of the DMS microparticles that were seen by optical microscopy to 
be associated with hydrated MCPS appear on the smooth PEC surface, 
thus confirming the entrapment of such particles within the PEC MCPS. 
SEM micrographs of lyophilized FD4 or drug-free MCPS are not shown, as 
quite similar to that in Fig. III.2. The high-resolution solid-state NMR 13C 
spectra of CMCh, TMC and lyophilized MCPS are reported in Fig. III.3., 
where an expansion of the spectral region of interest (40-120 ppm) is 
shown. The quite broad linewidth observed for all samples indicates a very 
low degree of structural order, already observed in chitosans in opposition 
to the high crystallinity of α-chitin [67-69]. Nevertheless, all signals in the 
TMC spectrum generally appear narrower than the corresponding signals 
for CMCh, because of the presence of faster reorientational motions. This 
is in agreement with the lack of hydrogen bonds in non-acetylated units, 
due to the presence of trimethylammonium groups [70]. The signals in the 
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13C spectra of the two polyions could be assigned by comparison with 
literature data and by semiempirical 13C chemical shift calculations as 
reported in Fig. III.3. 
In particular, the side-group carbon signals for both CMCh and TMC have 
been identified by acquiring selective 13C DE-MAS spectra, where the use 
of a 2s relaxation delay allows signals arising from nuclei experiencing 
high mobility to be relatively enhanced [71, 72]. In particular, the signal at 
55.6 ppm in the TMC spectrum was assigned to the methyl carbons of the 
trimethylammonium group, which are expected to undergo fast rotations, 
also corresponding to a very narrow signal at ≈3.5 ppm in the 1H MAS 
spectrum of TMC (not shown). The 13C CP- and DE-MAS spectra of 
lyophilized MCPS are reported in Fig. III.3.(f),(h), respectively, together 
with those obtained by mathematically adding up either the CP- or the DE-
MAS spectra of CMCh and TMC (Fig. III.3.(e),(g), respectively). The 
calculated spectra have the scope of highlighting possible dynamic or 
conformational changes occurring in the MCPS with respect to the pure 
CMCh and TMC components. Compared to the calculated spectrum, the 
experimental 13C CP-MAS spectrum of MCPS shows a significant 
broadening of the two signals at ≈99.2 and ≈55 ppm, possibly due to a 
reduction in the mobility of the TMC units with respect to the pure sample, 
and the displacement of the signal at 78.8 ppm, due to interactions with 
CMCh involving the C2 carbon of TMC. These observations are supported 
by the comparison between the experimental and calculated 13C DE-MAS 
spectra. In fact, the signal at ≈55 ppm is less intense in the experimental 
than in the calculated spectrum, clearly indicating a reduction of mobility 
for the CH3 trimethylammonium groups in MCPS, confirmed by the 
remarkable broadening of the peak at ≈3.5 ppm in the corresponding 1H 
MAS spectrum. 
In order to confirm these results and obtain more detailed and quantitative 
information on the molecular dynamics of these systems, an analysis of 
the 1H Free Induction Decay (FID) of CMCh, TMC, and MCPS samples 
acquired in lowresolution conditions was performed at room temperature. 
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Generally, the experimental intensity vs time signal produced in a solid 
sample by the on resonance excitation of 1H nuclei can be reproduced 
through a linear combination of different analytical functions by means of a 
suitable nonlinear leastsquares fitting procedure. Each function 
corresponds to a different dynamic domain of the sample [73]. The 
bestfitting parameters of the function are related to the dynamic behaviour 
of the domain, while the percent weight of the function is proportional to 
the number of protons present in the domain. In all cases the FID was well 
reproduced by a linear combination of Gaussian, Weibullian and 
exponential functions, having the general expression:   n2-(t/T )f(t) = e . 
Here, n is equal to 1, 2, and to a number between 1 and 2, for exponential, 
Gaussian and Weibullian functions, respectively; T2 is the spin-spin 
relaxation time, which increases with increasing molecular mobility. The 
results of the FID analysis of CMCh, TMC and MCPS samples are 
reported in Table III.2. Both TMC and CMCh are characterized by a very 
rigid fraction, described by a Gaussian function with a weight of 58-59% 
and a T2 of less than 20 µs; the remaining fraction is represented by an 
exponential function with a T2 of 300 µs for CMCh, and by a 2nd Gaussian 
function (T2 ≈ 60 µs) together with a very slowly decaying Weibullian 
function (T2 of the order of ms) for TMC. Therefore, the rigid fraction of 
both these samples, reasonably associated with protons on the polymeric 
main chains, shows similar dynamic behaviour; on the contrary, the most 
mobile fraction, essentially identified with the side chains, experiences 
much faster dynamics for TMC, in agreement with the presence of a 
trimethylammonium group for which the reorientational motions should 
take place with a very low energetic barrier. 
Like for CMCh, the FID of the MCPS sample can be well reproduced by a 
linear combination of a Gaussian and an exponential function. However, 
now both these functions are characterized by shorter T2 values, indicating 
a general decrease of mobility. This change is particularly important in the 
mobile fraction, where T2 decreases by a factor of 2 with respect to CMCh 
and by one order of magnitude with respect to TMC. This is in agreement 
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with the most significant changes observed in the 1H MAS spectrum of 
MCPS with respect to the pure polyions, showing the broadening and 
displacement of the sole peaks corresponding to the CH2 group of CMCh 
and CH3 group of TMC, both belonging to side-groups, confirming the 
high-resolution 13C results. 
These are clear indications of the presence, in the MCPS, of interactions 
between the most mobile moieties of CMCh (N-carboxymehtyl) and TMC 
(trimethylammonium). Furthermore, it must be noted that the lyophilized 
MCPS sample subjected to compression to give a tablet showed the same 
1H FID behaviour as the non-compressed sample (results not shown), thus 
indicating that sample compression causes no changes of dynamic 
properties at a molecular level. 
 
III.3.2 Drug Release from PEC MCPS 
For studying drug release from MCPS, the gastric environment was 
avoided because the PEC would dissociate and dissolve at acidic pH. At 
this pH, indeed, the carboxyls of CMCh become non-ionized, the 
interpolymer interactions weaken dramatically, and both component 
polymers of the PEC are soluble. Hence, release was studied at pH 7.4 
(SIF). The lyophilized MCPS would readily hydrate and disperse in SIF. 
However, the release of either FD4 or DMS was complete in 2 h, a term 
inadequate for a sustained-release system. Such a comparatively rapid 
release is ascribed to a high porosity of the PEC hydrogel and a high 
specific surface area of the MCPS. In order to drastically reduce the latter, 
MCPS were compressed into tablets, the swelling and drug release 
properties of which were investigated. 
 
III.3.2.1 Swelling and Release Properties of Tablet Matrices Based on 
PEC MCPS 
The swelling profiles of tablet matrices obtained from PEC MCPS, 
loaded with FD4 or DMS, or drug free (control), are shown in Fig. III.4., 
while the relevant release data are presented in Fig. III.5. As can be 
58 
 
  
verified, the swelling ratio in all cases attained 80% of its maximum value 
in less than 1 h, whereas the dose fraction released in an hour’s time was 
always about 20%. Hence, drug release was not governed by matrix 
swelling. Probably, the swollen hydrogel acted as a diffusional barrier 
influencing the release kinetics. 
The profiles in Fig. III.4. show that the matrices loaded with either FD4 or 
DMS absorbed water to increase their weights about 7-fold in 2-3 h. These 
findings confirm the high porosity of the PEC walls of the hydrated MCPS 
that was deduced from release data in the preceding section. 
The swelling of matrices obtained from drug-free MCPS was significantly 
lower, which might be related to a denser packing of the drug-free MCPS 
lyophilizate. Although the swelling kinetics were measured over 6 h, 
nevertheless the matrices were kept in water at 37°C for 24 h. Over this 
period no sign of matrix disintegration was observed. Also, the matrices 
retained their original shape despite the swelling. In order to evaluate the 
potential of tablets as drug delivery systems, their transit through ileum 
and ascending colon was simulated. When the ileum pH of 7.4 was 
changed into the pH of the ascending colon (5.5-6), a gradual 
disintegration at the matrix surface with liberation of the original MCPS 
was observed. On the other hand, when the whole release experiment 
was run with phosphate buffer pH 7.4 as the dissolution medium no 
apparent disintegration occurred. 
This is considered both a consequence and a sign of the pH-sensitiveness 
of the PEC. In order to ascertain whether the salts of the buffer would play 
a specific role, either an acetate or a phosphate pH 6 buffer was used to 
simulate the ascending colon environment: no apparent difference in the 
disintegration phenomenon was noticed. A visual comparison of release 
data in Fig. III.5., obtained with different elution patterns, suggests that 
such a phenomenon produced a significant effect on the release kinetics 
of either DMS or FD4 and that the effect was independent of the particular 
pH-6 buffer. For a statistical treatment, Eq. III.1 was fitted to the release 
data obtained with the different elution patterns and the resulting 
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parameters were compared on the basis of the respective confidence 
intervals. The fitting is good in all cases, as appears from the data points 
and respective calculated curves in Fig. III.5. up to 50-60% release, and 
from the relevant r2 values in Table III.3. A survey of this table shows that 
in neither the DMS nor the FD4 case is the rate parameter, K, significantly 
different for the different elution patterns. As for the time exponent, n, in 
both of the DMS and FD4 cases the values of this parameter for the SIF(2 
h)-SACE/PB(4 h) and SIF(2 h)-SACE/AB(4 h) patterns are not significantly 
different from each other whereas they are significantly higher than the 
value for the SIF(6 h) pattern. This analysis confirms matrix disintegration 
being pH-dependent, and quantifies the effect of this phenomenon to 
reduce the curvature of release profile and the decline of release rate. A 
similar behaviour is predicted of matrices administered in vivo to the ileum. 
A further release experiment was aimed at verifying whether the enzymatic 
hydrolysis of glycoside bonds in the chitosan backbone, known to occur in 
the ascending colon [74-76], would exert some effect on the release 
profile. To this purpose the release from the FD4 matrix was measured by 
applying the elution pattern SIF(2 h)-SACE/PB/CC(4 h). Rat cecal 
microflora was used because of the similarity with human intestinal 
microflora [77]. FD4 was chosen because with this model drug a volume of 
SACE/PB/CC sufficient to ensure sink conditions during the release 
experiment could be prepared using the cecal con- tents from a single rat. 
The release profile obtained by this elution pattern (not reported) was 
superimposable to that obtained in the absence of enzymes, i.e., with the 
SIF(2h)-SACE/PB(4 h) pattern, reported in Fig. III.5.(b). Since no enzyme 
effects on release kinetics could be evidenced, it can be concluded that 
the enzyme degradation of the chitosan backbone is slower than FD4 
release from matrix. 
 
III.3.2.2 Realizing Controlled Drug Release to Proximal Colon 
The PEC-based matrices were designed to start drug release in the 
distal small intestine and complete it in the proximal colon. 
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To realize this purpose the drug delivery system should prevent drug 
release in the stomach and the proximal small intestine. It was shown that 
hydroxypropylmethylcellulose capsules, enteric-coated with Eudragit® FS 
30 D by an industrially viable process, disintegrated towards the distal 
small intestine and proximal colon [78]. Capsules of this type, of size 00, 
could be used to carry the present matrices through the upper GI tract as 
far as the ileum, where they would be liberated intact, ready to start drug 
release. Alternatively, the matrices could be enteric-coated directly. The 
latter process was actually attempted in the present work, using Eudragit® 
S100 as the film-forming polymer, insoluble at pH<7, and methanol as the 
solvent. The release from enteric-coated DMS PEC-based matrices was 
measured in vitro, applying a SGF(2 h)-SJF(2 h)-SIF(2 h)-SACE/PB(4 h) 
elution pattern, intended to simulate matrix transit across stomach, 
proximal small intestine, distal small intestine, and proximal colon. 
The resulting release profile, presented in Fig. III.6. shows an initial burst, 
ascribed to the release of some DMS having diffused from matrix into the 
Eudragit film during the coating process, followed by a stop of release at 
the jejunum pH of 6.8. 
As soon as the protective film dissolved, upon attainment of the ileum pH 
of 7.4, drug release took place with a pattern corresponding to that of the 
uncoated matrix shown in Fig III.5.a, squares. 
The data demonstrate that the release was effectively hindered by the 
enteric film during matrix transit across stomach and proximal small 
intestine, and that the coating process induced no modification of the 
release properties of matrix in the distal small intestine and proximal colon. 
 
III.4 Conclusions 
The oppositely charged polyelectrolyte chitosan derivatives CMCh 
and TMC have shown the ability to form a PEC at neutral pH. PEC MCPS 
have been shown to be formed by virtue of the comparatively high 
viscosity of CMCh. Such MCPS have entrapped either a solution of a 
macromolecular drug model or a microparticulate dispersion of a sparingly 
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soluble drug. MCPS are not, as such, able to adequately sustain drug 
release, because of a high specific surface and a high porosity of the 
hydrated PEC, yet they can readily be lyophilized and compressed into 
tablets which, once enteric coated with Eudragit S100, represent potential 
devices for the controlled and sustained delivery of macromolecular or 
sparingly soluble drugs to the distal small intestine and proximal colon. It 
has been demonstrated by solid-state NMR that the formation of the PEC 
between CMCh and TMC is due to electrostatic interactions between the 
carboxylate groups of CMCh and the quaternary ammonium groups of 
TMC. Because the former are pH-sensitive, the PEC itself is pH-sensitive. 
In fact, the change of the environmental pH from ileum to proximal colon 
caused some liberation of MCPS from the matrix surface, which 
contributed to sustaining the release rate. The present PEC MCPS have 
the essential advantage of providing a means of uniformly loading 
controlled doses of macromolecular or microparticulate drugs into a 
physically crosslinked hydrogel matrix. Indeed, the drug load could in 
principle be readily modulated by varying the drug concentration in the 
CMCh solution used to prepare the MCPS. An important issue with the 
present MCPS is the entrapment efficiency, which has proved very low 
with the model macromolecular drug. This issue is supposed to be 
addressed when dealing with a real drug, the encapsulation efficiency of 
which would have to be optimized. It should be considered in this respect 
that polypeptide drugs might show an interactivity with the PEC much 
stronger than that showed by FD4. Another problem, i.e., the poor flow 
properties of the lyophilized MCPS, will have to be addressed when 
transferring the MCPS compression process from laboratory to industrial 
scale. 
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TABLES 
 
Table III.1. – Characteristics of the microencapsulation process. Means ± SD (n = 8) 
Drug Outputa MCPS size Range, µm DLb, % EEc, % 
- 0.838 ± 0.002 20-10 - - 
FD4 0.840 ± 0.016 20-10 2.5 ± 0.1 2.1 ± 0.1 
DMS 0.657 ± 0.007 20-10 3.7 ± 0.1 24.3 ± 2.5 
a
 Grams of lyophilizate per gram of CMCh. 
b
 
Drug load in MCPS. 
c
 Entrapment Efficienty. 
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Table III.2. – Best Fitting Parameters Obtained from the 1H FID Analysis of CMCh, 
TMC and Lyophilized MCPS Samples Using a Linear Combination of Functions. 
Sample 
Function 
Gaussian Gaussian Weibullian Exponential 
w, % T2, µs w, % T2, µs n w, % T2, µs w, % T2, µs 
TMC 57.7 19.4 14.1 61.6 1.36 28.2 1.87 - - 
CMCh 59.3 16.6 - - - - - 40.7 300 
MCPS 70.7 13.9 - - - - - 29.3 135.4 
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Table III.3. – Parameters Obtained from the Fitting of Eq. III.1 to the Release Data of 
Fig. III.5. 
Drug Eluition Pattern K ± SE (CI)a n ± SE (CI)a r2 
DMS SIF(2h)-SACE/PB(4h) 20.8 ± 0.30  
(20.1 to 21.5) 
0.60 ± 0.01  
(0.58 to 0.62) 
0.9982 
 SIF(2h) – SACE/AB(4h) 20.0 ± 0.50  
(19.0 to 21.1) 
0.60 ± 0.02  
(0.56 to 0.63) 
0.9954 
 SIF(6h) 19.3 ± 0.40  
(18.4 to 20.2) 
0.48 ± 0.01  
(0.45 to 0.51) 
0.9940 
FD4 SIF(2h) – SACE/PB(4h) 21.7 ± 0.41  
(20.7 to 22.7) 
0.72 ± 0.02  
(0.68 to 0.76) 
0.9979 
 SIF(2h) – SACE/AB(4h) 21.7 ± 0.75  
(19.8 to 23.5) 
0.74 ± 0.03  
(0.66 to 0.81) 
0.9935 
 SIF(6h) 21.2 ± 0.71  
(19.5 to 23.0) 
0.59 ± 0.03  
(0.51 to 0.66) 
0.9904 
a
 Confidence Interval. 
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FIGURES 
 
 
 
Figure III.1. – Photograph of macroscopic capsules obtained by dripping a CMCh 
solution into a solution of an excess TMC. 
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Figure III.2. – SEM micrograph showing a lyophilized microcapsule containing DMS. 
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Figure III.3. – Expansion of the high-resolution solid-state NMR 13C CP-MAS and DE-
MAS spectra of CMCh and TMC (left), and lyophilized MCPS (right). (a), (b), (f) and 
(e): 13C CP-MAS spectra of CMCh, TMC, MCPS (experimental), and MCPS 
(calculated), respectively. (c), (d), (h) and (g): 13C DE-MAS spectra of CMCh, TMC, 
MCPS (experimental), and MCPS (calculated), respectively. CP spectra were acquired at 
a spinning speed of 6 kHz, using a contact time and a relaxation delay of 0.5 ms and 5 s 
for both CMCh and TMC, and 0.2 ms and 10 s for the MCPS sample, respectively. DE 
spectra were acquired at a spinning speed of 6 kHz, using a relaxation delay of 2 s. The 
MCPS calculated spectra were obtained by mathematically adding up the corresponding 
spectra of CMCh and TMC. 
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Figure III.4. – Swelling (ratio of swollen to initial dry weights) profiles in water of 
DMS, FD4 and drug-free (control) PEC-based matrices obtained by MCPS compression. 
Data points are the means±SD of at least three values.  
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Figure III.5. – Release profiles obtained by applying different elution patterns to DMS 
(a) or FD4 (b) PEC-based matrices obtained by MCPS compression. Data points are the 
means±SD of at least four values. Lines show the fitting of Eq. III.1 to release data. 
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Figure III.6. – Data on DMS release from enteric-coated PEC-based matrices obtained 
by MCPS compression. Elution pattern, SGF(2h)-SJF(2h)-SIF(2h)-SACE/PB(4h). Data 
points are the means±SD of at least four values. 
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SECTION IV - Novel Multifunctional Chitosan Conjugates as 
enhancers of intestinal drug permeability 
 
IV.1 Introduction 
Numerous literature reports deal with chitosan derivatives 
containing thiol groups, such as chitosan-cysteine, chitosan-thioglycolic 
acid, chitosan-4-thiobutylamidine, chitosan-2-iminothiolane, and chitosan-
N-acetylcysteine conjugates [80-86]. These thiolated chitosans have 
numerous advantages over the parent chitosan, in that they have shown 
improved mucoadhesive and permeation enhancing properties. However, 
they are insoluble at the neutral pH of numerous physiological 
environments. 
The N+Ch conjugates, the synthesis of which has been described in  
SECTION II, contain residual unsubstituted primary amino groups on the 
polymer backbone. These groups have been used for the covalent 
attachment of thiol-containing moieties to the polymer backbone, following 
the scheme illustrated in Fig. IV.1., so as to obtain multifunctional chitosan 
derivatives soluble at neutral pH. Such derivatives are intended to be 
tested ex vivo on the excised rat intestinal epithelium to evaluate their 
potential transmucosal absorption enhancement properties. FD4 (MW 
4400 Da) is used as a model of water-soluble macromolecular drugs such 
as, e.g., polypeptide drugs. 
 
IV.2. Materials and method 
 
IV.2.1 Materials 
Fluorescein isothiocyanate dextran, MW 4400 Da (FD4), 3-(2-
pyridyldithio)propionic acid N-hydroxysuccinimide ester, NaBH4, trypan 
blue (Sigma), 2-diethylaminoethyl chloride (DEAE-Cl) hydrochloride 
(Fluka); chitosan (minimum 90% deacetylated) from shrimp shell (Ch) 
(Chito-clear FG90, Primex, Drammen, Norway) were used. The 
commercial Ch had an average viscometric molecular weight of 590 kDa. 
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The deacetylation degree, determined by IR or NMR, was 90% or 82%. 
The quaternary ammonium-chitosan conjugates, N+Ch, were synthesized 
as described by Zambito et al. (see, e.g., ref. [31]). Their substitution 
degree was 40%, with an n value of 3 (code N+40) or 60%, with an n value 
of 1.7 (code N+60). 
 
IV.2.2 Synthesis and characterization of multifunctional derivatives of 
chitosan 
Twenty ml of a 0.46% w/v ethanolic solution of 3-(2-
pyridyldithio)propionic acid N-hydroxysuccinimide ester were added 
dropwise to 50 ml of a 0.5% w/v aqueous solution of N+40 or N+60 (molar 
ratio between polymer repeating unit and reagent, 1:10) or to 25 ml of the 
N+60 solution (polymer/reagent molar ratio, 1:20). The reaction mixture 
was stirred for 30 min at ambient temperature. A portion of this mixture 
was purified by dialysis (membrane, Spectra/Por®, molecular weight cut-off 
3500 Da, Spectrum Laboratories Inc, Rancho Dominguez, CA, USA) and 
then lyophilized. The product obtained from this 1st step of the synthesis, 
indicated in Fig. IV.1., was characterized by 1H NMR spectroscopy (10 
mg/ml in D2O, Varian spectrometer 600 MHz, operating at 25±0.1 °C). 
The remaining portion of the reaction mixture was subjected to the 2nd step 
of the synthesis, by adding 1.5 ml of a 5% w/v aqueous solution of NaBH4 
(disulphide/NaBH4 molar ratio, 1:3). After 8 h of stirring the mixture was 
subjected to dialysis, as indicated above, over two days, after which the 
purified product was lyophilized. The obtained polymer was characterized 
by 1H NMR spectroscopy, as described above.  
The degree of substitution of the thiol-bearing moieties was determined by 
iodometric titration of the –SH groups. Six mg of each conjugate were 
dissolved in 2 ml water, then the pH was adjusted to 2-3 with 1M HCl and 
1 ml 1% w/v starch solution was added. Samples were then titrated with 1 
mM aqueous iodine until a persistent light blue discoloration was observed 
[82]. 
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IV.2.3 Permeation experiments 
The apparatus and procedure used for the permeation studies have 
already been described in Section II.2.4. FD4 was used as the permeant 
in the present instance. The apical to basolateral transport of the drug 
model was investigated in the absence or presence of the polymer under 
test (0.1, 0.5 or 1 % w/v) in the donor. At 30 min intervals over 180 min, 
100 µl samples were withdrawn from the receptor chambers and replaced 
by the same volume of fresh medium. The amount of permeated drug 
model was determined by HPLC, as already described [26]. 
 
IV.2.4 Measurement of drug-polymer interactions 
A previously described method, based on the dynamic dialysis 
technique [20], was used as described in Section II.2.5 to determine the 
drug-polymer interactions in the donor phase of the permeation 
experiments referred to in the preceding section. Drug flux through a 
porous cellulose membrane (molecular weight cut-off, 10000-12000 Da) 
under quasi-steady state conditions was measured in the presence or 
absence of the polymer in the donor phase. The polymer and initial drug 
concentrations in the donor were equal to those used in the ex vivo 
permeation experiments, referred to in Section IV.2.3. The receptor was 
analysed for the drug by HPLC, as already described [26].  
The regression for the fitting of dialysis data, expressed as drug 
concentration in the donor vs. time, to 1st order kinetics was always 
significant (r2≥ 0.97, n≥ 8). This allowed calculation of the fraction of free, 
non-interacting drug, fF, as described in Section II.2.5. 
Permeation data were treated as previously described in Section 
II.2.6. 
 
IV.2.5 Test of viability of epithelial cells 
This test was carried out as described in Section II.2.7 and yielded 
the same result concerning the viability of epithelial cells. 
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IV.3 Results and discussion 
 
IV.3.1 Synthesis of multifunctional derivatives of chitosan 
N-succidimidyl 3-(2-pyridyldithio)propionate is a bifunctional reagent 
containing an N-hydroxysuccinimide ester group and a 2-pyridyl disulphide 
group. The N-hydroxysuccinimide ester reacts with the free primary amino 
groups still present on the N+Ch backbone to yield stable amide bonds. 
This reaction is fast in very mild conditions in an aqueous environment 
[87]. 
The 1H NMR spectrum reported in Fig. IV.2.a for the product from the 1st 
step of the synthesis shows signals in between 7 and 8.5 ppm, which can 
be assigned to the protons of the pyridine ring bound to the disulphide 
group. This indicates that the amide bond has formed according to the 
predicted 1st step of the synthesis, shown in Fig.IV.1. 
The pyridine signals are absent from the 1H NMR spectrum for the product 
from the 2nd step of the synthesis, reported in Fig. IV.2.b. This is 
interpreted as a proof of the reduction of the -S-S- to –SH groups, with 
detachment of the pyridine moiety. 
The characteristics of the multifunctional derivatives of chitosan obtained 
from the synthesis are listed in Table IV.1. In their code, N+x-SHy, x and y 
represent the degree of substitution of the pendant chains containing 
adjacent quaternary ammonium groups and thiol groups, respectively. It 
appears from the data that the degree of substitution of thiol groups, y, is 
related inversely to the degree of substitution of the starting N+Ch polymer, 
x, because a more substituted N+Ch has less free amino groups available 
for thiolation. Besides, for a given degree of substitution of the N+Ch 
polymer the degree of thiolation depends directly on the reagent excess 
used in the synthesis. Thus, a comparatively high thiolation degree (21%) 
was obtained from the more substituted N+60 by doubling the reagent 
excess. 
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IV.3.2 Permeation experiments 
The excised rat jejunum was chosen among the known intestinal 
epithelium models for the permeability enhancement studies because its 
tight junctions are similar in tightness and number to those of the human 
jejunum [49] and because the chitosan derivatives under study are 
expected to act by modulating intercellular tight junctions [55]. The N+Ch 
conjugates have shown more ability to enhance the permeability of FD4 
across the excised rat intestinal mucosa than the known N-trimethyl 
chitosan [79]. The relevant Papp and ER values in Table IV.2. indicate that, 
of the N+Ch conjugates N+60, having a higher substitution degree and a 
lower n value compared to N+40, is a more effective permeability enhancer 
for FD4 than N+40. Interestingly, the Papp and ER data in the table for the 
multifunctional polymers indicate that N+60-SH5 e N+40-SH9 are more 
effective permeability enhancers for FD4 than the respective parent 
polymers N+60 and N+40. The thiolated polymers maintained the same 
rank order of effectiveness as the parent polymers, although the thiolation 
degree of N+40-SH9 is higher than that of N+60-SH5. This finding indicates 
that the quaternary ammonium groups in the thiolated polymers still play a 
fundamental role in the permeability-enhancing mechanism. In fact, the 
derivative N+60-SH21, having a comparatively high thiolation degree, has 
appeared ineffective, possibly because the substituted thiol-bearing 
groups would hinder the ionic interaction between the quaternary 
ammonium groups of the polymer and the negatively charged sites on the 
epithelial membrane. The data in Table IV.2. altogether point to a 
synergism between quaternary ammonium and thiol groups in the 
enhancing action of the present multifunctional polymers on FD4 
permeability across the intestinal mucosa. However, an excessive 
thiolation is counterproductive. 
The fF values in Table IV.2. point to a significant binding of FD4 by the 
multifunctional polymers, which can be ascribed to an ionic interaction 
between the anionic FD4 and the polycationic polymer. Moreover it is 
observed that the fF values increase with increasing degree of thiolation of 
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such polymers, probably because the presence of the thiol-bearing groups 
is of hindrance towards the ionic drug-polymer interaction. In a previous 
work [79] we observed that N+60, i.e., the most effective N+Ch  enhancer 
of FD4 intestinal permeability, produced no significant increase of the 
cumulative FD4 transport across the excised rat intestine over the whole 
time of experiment, T3h, because of a lag time significantly higher than that 
of the control. On the other hand, Table IV.2. shows lag times, obtained 
with the present multifunctional polymers N+60-SH5 and N+60-SH9, not 
significantly different from the value for the control. Hence, with these 
polymers T3h values significantly higher than either that for the control or 
those for the parent N+60 and N+40 polymers were obtained, as shown by 
the relevant data in Table IV.2.. Then our multifunctional chitosan 
derivatives, in addition to being more effective as permeability enhancers 
than the parent N+Ch polymers, are prompter in their action. The effect of 
increasing concentrations of N+60-SH5, i.e., the most effective 
multifunctional polymer, on Papp is seen in Table IV.3. Here the ER values 
appear to be directly correlated with the polymer concentration. It is 
worthwhile noting that with a 1% w/v concentration of this polymer the lag 
time drops dramatically, testifying to a prompt action, and the T3h value is 
significantly higher than that for the control, in fact, it is the highest of the 
polymer concentrations tested, despite a most pronounced drug-polymer 
binding, testified by the lowest fF value. 
 
IV.4. Conclusions 
The quaternary ammonium-chitosan conjugates N+40 and N+60, 
having free primary amino groups, have allowed the covalent attachment 
of thiols to these groups via the formation of 3-mercaptopropionamide 
moieties. The resulting N+40-SH9 and N+60-SH5 multifunctional chitosan 
derivatives have improved the ability of the parent N+40 and N+60 
polymers to enhance the permeability of FD4, a model of water-soluble 
macromolecular drugs, across the excised rat intestinal mucosa. FD4 is 
supposed to penetrate the intestinal epithelium via the paracellular route, 
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so the present polymeric enhancers probably act by opening the tight 
junctions joining the epithelial cells. The data altogether point to a 
synergism between quaternary ammonium and thiol groups in the action 
of the present multifunctional polymers. However, an excessive thiolation 
is counterproductive because too numerous thiol-bearing groups may 
hinder the permeability-enhancing ionic interaction between the 
quaternary ammonium groups of the polymer and negatively charged sites 
on the epithelial membrane or in the tight junctions. The enhancement 
effect has appeared to be directly correlated with the polymer 
concentration. In fact, the strongest and promptest effect has been exerted 
by N+60-SH5 at the concentration of 1% w/v. 
The present multifunctional chitosan derivatives are safe on the intestinal 
epithelium cells, as demonstrated by the viability test.  
It could be of interest to ascertain, in the future, whether these polymers 
are able to facilitate the transcellular, in addition to the paracellular, drug 
penetration route across the intestinal mucosa, through the use of a tracer 
of the former route, such as, e.g., the lipophilic rhodamine 123. Moreover, 
possible permeability-enhancing effects of these polymers on other 
mucosal epithelia, such as the corneal and nasal ones, are open to 
investigation. 
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TABLES 
 
Table IV.1. - Structural characteristics of the N+x-SHy chitosan conjugates. 
Polymer code xa (%) nb Reagent excessc yd (%) 
N+40-SH9 40.6 ± 1.3 3.0 ± 0.2 10:1 9.1 ± 1.0 
N+60-SH5 59.2 ± 4.5 1.7 ± 0.1 10:1 5.5 ± 0.7 
N+60-SH21 59.2 ± 4.5 1.7 ± 0.1 20:1 21.0 ± 0.5 
aDegree of substitution of pendant chains containing quaternary ammonium groups. 
bNumber of quaternary ammonium groups in pendant chains. creagent/chitosan repeating 
unit molar ratio used in the synthesis. dDegree of substitution of thiol groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80 
 
  
Table IV.2. - Data on FD4 permeation across excised rat jejunal epithelium from Ringer 
buffer pH 6.8 containing 0.2% w/v FD4 and 0.5% w/v of different chitosan derivatives. 
Means±SD of at least 6 runs. 
Polymer code Flux ± SD 
(µg cm-2 h-1) 
La (h) fFb Pappc ± SD  
(cm sec-1 106) 
ERd T3he  
(µg cm-2) 
Control 21.6±5.3 0.45±0.10 - 3.0±0.7 - 55.1± 5.4 
N+40 20.2±3.9* 0.49±0.14 0.62 4.5±0.9* 1.5 52.3± 3.7 
N+60 29.1±7.5* 0.99±0.17* 0.63 6.4±1.6* 2.1 58.5± 6.6 
N+40-SH9 39.7±7.1* 0.40±0.12 0.71 7.8±1.4* 2.6 93.0±18.0* 
N+60-SH5 46.1±9.4* 0.53±0.20 0.63 10.2±2.1* 3.4 94.2±14.1* 
N+60-SH21 20.8±2.3 0.42±0.11 0.84 3.4±0.4 1.2 49.1± 4.6 
aPolymer codes are explained in Table IV.1. and Section IV.3.1., b Lag time; c FD4 
fraction free from polymer binding; d Apparent permeability; e Enhancement ratio, f 
Cumulative transport over the whole time of experiment (3h). The data marked by * are 
significantly different from the respective controls (P<0.05).  
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Table IV.3. - Data on FD4 permeation across excised rat jejunal epithelium from Ringer 
buffer pH 6.8 containing 0.2% w/v FD4 and different concentrations of N+60-SH5. 
Means±SD of at least 6 runs. 
Polymer Conc. 
(%w/v) 
Flux ± SD 
(µg cm-2 h-1) 
La (h) fFb Pappc ± SD 
(cm sec-1 106) 
ERd T3he 
(µg cm-2) 
- 21.6±5.3 0.45±0.10 - 3.0±0.7 - 55.1±5.4 
0.1 25.6±7.1 0.42±0.11 0.94 3.8±1.0 1.3 58.7±6.9 
0.5 46.1±9.4 0.53±0.20 0.63 10.2±2.1* 3.4 94.2±14.1* 
1 44.4±10.7 0.07±0.01* 0.37 16.7±4.0* 5.6 136±20.2* 
a
 Lag time; b FD4 fraction free from polymer binding; c Apparent permeability; d 
Enhancement ratio;  e Cumulative transport over the whole time of experiment (3h). The 
data marked by * are significantly different from the respective controls (P<0.05).  
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FIGURES 
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Figure IV.1. - Synthesis scheme of the N+x-SHy chitosan conjugates. 
N+x-SHy 
N+Ch 
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Figure IV.2. - 1H NMR spectrum in D2O of the a) product of the 1st step of the synthesis; 
b) product of the 2nd step of the synthesis. 
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SECTION V - Selected Polysaccharides at Comparison for 
their Mucoadhesiveness and Effect on Precorneal 
Residence of Different Drugs in the Rabbit Model 
 
V.1 Introduction 
Eyedrops is currently the dosage form of choice for the topical 
treatment of ocular diseases, essentially because it is the best accepted 
by patients.  
Treatment with eyedrops, however, poses the issue of a poor 
bioavailability because the precorneal area, i. e., the site of drug 
action/absorption, is rapidly cleared of drugs by protective mechanisms of 
the eye, such as blinking, basal and reflex tearing, and nasolacrimal 
drainage. This implies the need of frequent instillations, and hence, the 
risk of side effects. Increasing ocular bioavailability, thereby decreasing 
the frequency of instillations, remains a stimulating challenge for the 
formulators of eyedrops. 
An approach to the task has been the reduction of drainage rate 
by increasing the viscosity of the preparation [88-92] or resorting to 
mucoadhesive polymers [93]. 
Mucomimetic polysaccharides, such as xyloglucan (tamarind seed 
polysaccharide), hyaluronic acid, hydroxyehtylcellulose, which are 
currently used in commercial artificial tears for the treatment of the dry eye 
syndrome, may as well prolong the residence of ophthalmic drugs in the 
precorneal area in virtue of their mucoadhesive properties. The ability of a 
polymer to improve ocular bioavailability of drugs by adhering to the ocular 
surface and binding the drug to it is a more promising property than the 
polymer viscosifying power, so far as fluid solutions are better tolerated 
than viscous ones [94]. 
In the present work the above polysaccharides have been put to 
comparison on the ground of their adhesiveness to the ocular surface and 
their ability to prolong the residence of the antiallergic ketotifen or the 
antiinflammatory diclofenac in the precorneal area of the rabbit eyes.  
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In addition to factors pertaining to the polymer, such as molecular weight, 
functional groups, molecular conformation or chain flexibility and mobility, 
mucoadhesion is influenced by environmental factors that determine 
polymer charge, hydration or swelling degree [95].  
Therefore care was taken to distinguish mucoadhesion from viscosity 
effects. To this purpose the rank order of polymer precorneal clearance 
resulting from in vivo tests was compared with that of mucin-polymer 
interactivity resulting from an in vitro method based on the measurement 
of the effect of mucin-polymer interaction on the viscosity of a system of 
porcine gastric mucin and polysaccharide in solution [96]. 
The rabbit model has also been used to assess the effects of the 
polysaccharides on the time of residence of ketotifen fumarate or 
diclofenac sodium in the tear fluid. Each of these drugs is the active 
principle of commercial eyedrops, the former for the treatment of allergic 
conjunctivitis, the latter to treat inflammation and swelling of the eye 
following cataract surgery. 
Molecular drug-polymer binding is of great relevance to the drug residence 
time in tear fluid. Such a binding has been quantified by the timehonored 
method of the dynamic dialysis, basically consisting in measuring the 
polymer effect on the drug permeation rate across a membrane permeable 
to the drug, impermeable to the polymer [97]. 
It must be recognized that the precorneal clearance determined in rabbits 
is not representative of that in humans, mainly due to differences in 
blinking frequency [90,98,99,100]. Nevertheless, the effects of blinking can 
be considered to be similar for the different preparations tested, then the 
rabbit model is deemed robust for the comparative purposes of the 
present work. 
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V.2 Materials and methods 
 
V.2.1 Materials 
Ketotifen fumarate (KF)(Sifavitor S.p.A., Lodi, Italy), diclofenac 
sodium (DS)(Corden Pharmachem NV, Landen, Belgium), tamarind seed 
polysaccharide (TSP)(Opocrin S.p.A., Modena, Italy), hyaluronic acid 
(HA)(Contipro, Dolní Dobrouč, Czech Republic) and hydroxyethylcellulose 
(HEC)(Natrosol®, Hercules Italia S.p.A., Milan, Italy) all were kindly gifted 
by Farmigea S.p.A. (Pisa, Italy). Fluorescein isothiocyanate (FITC) and 
porcine gastric mucin type III were purchased from Fluka and Sigma, 
respectively. All other chemicals and solvents were of reagent grade. 
 
V.2.2 FITC-Labeling of Polysaccharides 
A previously described procedure was followed [45, 101]. A solution 
of FITC in dimethyl sulfoxide (1 ml, 2 mg/ml) was added to an aqueous 
solution of TSP, HA or HEC (20 ml, 2 mg/ml) and the mixture was 
incubated at 4 °C for 8 h. Next the solution was passed through a column 
of Sephadex G15 in order to clear the labeled polymer of non reacted 
FTIC, then it was lyophilized. In no case did the Sephadex column retain 
any fluorescence, in all cases indicating the absence of non reacted FITC 
and the complete labeling of polymer. Hence the fluorophore bound to the 
polymer could be calculated at 5% of the total mass (0.13 mmol/g). 
 
V.2.3 Preparation of Ophthalmic Drops 
For comparing the polysaccharides for their adhesiveness to the 
ocular surface, ophthalmic drops containing 0.2, 0.5 or 0.7% w/v of each 
FITC-labeled polymer were prepared. The vehicle of FITC-TSP, FITC-HA 
and FITC-HEC was 0.0375 M phosphate buffer pH 7.4, made isotonic with 
sodium chloride(PBS). Medicated ophthalmic drops were prepared, 
containing 0.7 mg/ml KF or 1 mg/ml DS and 0.2% w/v or 0.7% w/v of TSP, 
HA or HEC in PBS. Each drug was dissolved in the vehicle before adding 
the polymer. For controls, polymer-free ophthalmic drops containing 0.7 
88 
 
  
mg/ml KF or 1 mg/ml DS in PBS were prepared. The isotonicity of 
ophthalmic drops was checked by a microosmometer (Hermann Roebling, 
Berlin, Germany). The solution containing 0.7 mg/ml KF and 0.7% w/v 
HEC in PBS was clear after its preparation at ambient temperature, but at 
35 °C, i. e., the temperature of the eye surface, it became milky with a fine 
precipitate, which indicated an incompatibility of ingredients under 
physiological conditions. Therefore this formulation was not retained for 
further studies. 
 
V.2.4 Viscosity Measurements 
Rheograms of non-medicated ophthalmic drops prepared as 
described above with non-FITC-labeled polymers were recorded at 35 °C 
with a Haake RS1 rheometer equipped with coaxial cylinders Z40 (rotor) 
and Z41 (stator). 
Data were acquired and analyzed using Rheo Win Pro software (Haake). 
The TSP solutions 0.2% w/v showed a newtonian behavior. The viscosity 
of these systems at 35 °C was measured by the Ostwald viscometer, 
which yielded more accurate values. Means of at least 3 measurements 
are reported in Table V.1.. The coefficient of variation of measurements 
never exceeded 0.4%. The viscosity of distilled water at 35 °C was 
assumed to be 0.7194 mPas [Handbook of Chemistry and Physics, 1975]. 
The TSP solutions 0.5 and 0.7% w/v, and the HA and HEC solutions 0.2, 
0.5 and 0.7% w/v showed a pseudoplastic behavior (rheograms not 
shown). For these systems the viscosity values were measured at the 
shear rate of 200 s-1, because at rates of this magnitude the dependence 
of viscosity on shear rate was minimal in all cases tested. Viscosity 
measurements showed insignificant differences between FITC-labeled 
and unlabeled polymers. 
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V.2.5 In Vitro Comparative Evaluation of Polysaccharide 
Mucoadhesiveness 
According to Hassan and Gallo [97] the viscosity coefficient, η, of a 
hydrophilic dispersion of mucin and a mucoadhesive polymer results from 
the additive contributions of the viscosity coefficients of mucin, ηm, and 
polymer, ηp, and a viscosity component due to mucin-polymer interaction, 
ηmp. After measuring η, ηm and ηp the interactive component was 
calculated as:    
ηmp=η-ηm-ηp                                                                                      Eq. V.1. 
ηmp values, determined at the rate of shear of 200 s-1, were used for a 
comparative evaluation of polymer mucoadhesiveness. 
Dispersions containing 15% w/v mucin and 0.2, 0.5 or 0.7% w/v 
polysaccharide in PBS (TSP, HA, HEC) were tested. The dispersions were 
prepared by adding 2 ml of polymer solution, at 4 fold the final 
concentration, to 6 ml of a 20% w/v mucin dispersion in the same solvent. 
The mucin-polymer systems and the dispersion of mucin alone showed a 
pseudoplastic rheological behavior. Their viscosity coefficients were 
measured at 35 °C by the Haake RS1 rheometer at the shear rate of 200 
s-1, i. e., the same as for the pseudoplastic polymers alone. 
  
V.2.6 Measurement of Elimination Kinetics from Tear Fluid of Rabbits 
Male New Zealand albino rabbits weighing 3.0-3-5 Kg, maintained 
under standard stabulation conditions, were used. They were treated as 
prescribed in the “Guide for the Care and Use of Laboratory Animals” (NIH 
Publication No. 92-93, revised 1985). All experiments were carried out 
under veterinary supervision, and the protocols were approved by the 
Ethical Scientific Committee of the University. 
 
V.2.6.1 Elimination Kinetics of Polysaccharides 
The non-medicated ophthalmic drops of FITC-TSP, FITC-HA, FITC-
HEC were tested. One drop of each solution (50 µl) was instilled into the 
lower conjunctival sac with care to avoid spillage. Tear fluid samples were 
90 
 
  
collected at various intervals from the lower marginal tear strip using 1.0 µl 
disposable glass capillaries (Microcaps, Drummond Scientific Co., 
Broomall, PA), which were flushed with 1.0 µl of water. After further 
dilution with 100 µl of water the samples were analyzed for the polymer. 
For each polymer at each concentration 8 elimination curves were 
obtained, each determined in a single eye of different animals. The 
analysis of samples was carried out by a fluorimetric method 
(spectrophotofluorimeter Perkin-Elmer LS 45). For FITC-TSP, FITC-HA 
and FITC-HEC the excitation was at 494 nm, the emission at 510 nm. 
Calibration curves were constructed using 6 standard aqueous solutions 
per polymer in the concentration range of 0.01-0.2 µg/ml for FITC-TSP, 
FITC-HA and FITC-HEC. In all cases the fluorescence vs. concentration 
plot was linear in the concentration range of the standards (r2>0.99). 
 
V.2.6.2 Elimination Kinetics of Drugs in the Presence of 
Polysaccharides 
The medicated ophthalmic drops were tested, following the 
procedure described in the above section for the non-medicated ones, 
except that the withdrawn tear fluid samples were diluted with 50 instead 
of 100 µl of water because the HPLC methods used for the analysis of the 
drugs had detection limits higher than the fluorimetric method used for the 
polysaccharides. The HPLC apparatus (Perkin-Elmer) consisted of Series 
200 pump, 20 µl Rheodyne injector, UV detector and Turbochrom 
Navigator HPLC software for data integration. A Spheri-5 RP18 250x4.6 
mm 5 µm column was used. 
For the analysis of KF, the mobile phase (flow rate 2.0 ml/min) was 
acetonitrile/water/triethylamine/glacial acetic acid (50:50:0.2:0.1), the UV 
detection was set at 301 nm. Standard curves were constructed by 
analyzing 6 standard KF solutions in PBS. The standard curves produced 
on different days were all linear (r2>0.99) in the concentration range from 0 
to 10 µg/ml (limit of determination, about 0.02 µg/ml). The retention time 
was 6.3 min. 
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For the analysis of DS the mobile phase (flow rate 1.5 ml/min) was 
acetonitrile/water/glacial acetic acid (50:46:4), the UV detection was set at 
276 nm. Standard curves were constructed by analyzing 6 standard DS 
solutions in PBS. The standard curves produced on different days were all 
linear (r2>0.99) in the concentration range from 0 to 25 µg/ml (limit of 
determination, about 0.03 µg/ml). 
The retention time was 5.8 min. With either KF or DS samples the 
concentration of each unknown analyzed on a given day was determined 
via the standard curve produced on the same day. 
 
V.2.6.3 Elimination Data Treatment 
The concentration in tear fluid (CTF) vs. time data, obtained with the 
nonmedicated and the medicated ophthalmic drops as described in the 
above sections, were used to calculate the mean residence time of each 
polysaccharide, or drug, in tear fluid (MRT). This parameter resulted from 
the ratio, AUMC/AUC, between the area under momentum curve (CTF t vs. 
t curve) and the area under the CTF vs. t curve. AUMC and AUC were 
calculated by the linear trapezoidal rule, between time 0 and the time 
when CTF dropped below the minimum quantifiable value. For each 
elimination curve the corresponding MRT was calculated, thus, for each 
case studied 8 MRT values were obtained, of which mean and SE were 
calculated. Difference significance between two means was evaluated by 
the Student’s t-test (P<0.05). 
With the medicated ophthalmic drops also the maximum residence time of 
the drug at quantifiable concentrations in tear fluid (RTmax) was reported. 
This time corresponded to the last point of the CTF vs. time plot for the 
drug. In this plot for each time interval the mean of 8 CTF values obtained 
with different animals was reported. The minimum quantifiable CTF value 
was 1.1 µg/ml for KF, 1.5 µg/ml for DS, considering the necessity to dilute 
the withdrawn samples at least 1:50 v/v. 
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V.2.7 Measurement of Drug-Polymer Interactions 
A previously described method, based on the dynamic dialysis 
technique [99, 104], was used as described in Section I.2.6 to determine 
the drug-polymer interactions in the ophthalmic drops. Drug flux through a 
porous cellulose membrane (molecular weight cut-off, 3500 Da) under 
quasi-steady state conditions was measured at 35 °C in the presence or 
absence of the polymer in the donor phase. The polymer and initial drug 
concentrations in the donor were equal to those used in the in the in vivo 
tests for the determination of the elimination kinetics of drugs in the 
presence of polysaccharides. The receptor was spectrophotometrically 
analyzed for KF, at 301 nm, or DS, at 276 nm. The regression for the 
fitting of dialysis data, expressed as permeant concentration in the donor 
vs. time, to 1st order kinetics was always significant (r2≥0.99, n≥8). This 
allowed calculation of the dialysis rate constant. Under the above 
experimental conditions, a reduction of the dialysis rate constant caused 
by a polymer was considered a sign and a measure of drug-polymer 
interactions. The fraction of bound, interacting permeant, fB, was 
expressed by the following equation [102]: 
                                                                             
where kp and ka represent the dialysis constants in the presence and in the 
absence of polymer, respectively. 
Values of fB were calculated, by Equation V.2., only for those cases where 
kp and ka were significantly different on the basis of the Student's t-test 
(P<0.05). 
 
 
V.3 Results and Discussion 
 
V.3.1Comparative Assessment of Polysaccharide Mucoadhesiveness 
In an attempt to assess the rank order of polysaccharide 
adhesiveness to the eye surface, the mucin-polymer interactivity, 
  
Eq.V.2. 
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determined in vitro by viscosity measurements, was compared with the 
mean residence time of polymer in the tear fluid of rabbits. All ophthalmic 
drops when instilled in rabbit eyes were biocompatible and caused no 
apparent irritation signs, such as conjunctival/corneal edema, hyperhemia 
nor mucus discharge. 
In Table V.1. the viscosity component due to mucin-polymer interaction, 
ηmp, and the percent contribution of this interactive component to the 
viscosity of the mucin-polysaccharide system, ηmp/η, are listed for each 
mucin-polysaccharide dispersion and compared with the mean residence 
time of polysaccharide in the tear fluid of rabbits, MRT. As can be 
observed, for all polymers the interactive component gives an important 
contribution to the overall viscosity of the dispersion. Such a contribution 
increases with increasing polymer concentration, as expected. 
These results are in agreement with the recognized mucoadhesiveness of 
the polysaccharides under study.  
For the concentration of 0.2% w/v the differences among the MRT values 
for TSP, HA and HEC are statistically insignificant. Because the viscosity 
of TSP at this concentration is lower than that of HA or HEC, it can be 
stated that the in vivo mucoadhesiveness of TSP 0.2% w/v is not lower 
than that of HA or HEC 0.2% w/v. This is confirmed by the relevant data in 
Table V.1. showing that, at this concentration, the in vitro interactivity of 
TSP with mucin is stronger than that of HA and similar to that of HEC. 
For the concentration of 0.5% w/v, the rank order of mucin-polymer 
interactivity is HEC>TSP>HA, whereas the mean values of MRT are in the 
order HEC≈HA>TSP. It must be considered, in this respect, that the MRT 
value can be directly influenced by the viscosity of the solution, in addition 
to the mucoadhesiveness of the polymer, and that, at this concentration, 
the viscosity of HEC, or HA is markedly higher than that of TSP. Then, at 
the concentration of 0.5% w/v the rank order of mucoadhesiveness is 
more accurately established by the method in vitro than by the in vivo 
evaluation of the MRT values, because the latter cannot discriminate 
between mucoadhesiveness and viscosity effects. 
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At the concentration of 0.7% w/v the order of in vitro mucinpolymer 
interactivity, resulting from the data in Table V.1., that is, HEC≈HA>TSP, 
disagrees with that of the MRT values, which is TSP>HEC≈HA. This 
cannot be explained by a direct influence of the solution viscosity on MRT 
because, at this concentration, the viscosity of TSP is much lower than 
that of HEC or HA. The above discrepancy between in vitro and in vivo 
data could be explained by admitting that, although no appreciable 
irritation of the rabbit eyes was ever observed, when the viscosity of the 
ophthalmic drops was too high, such as in the cases of HEC and HA 0.7% 
w/v, reflex tearing was particularly abundant and caused dilution of 
polymer in tear fluid, with consequent decrease of both viscosity of such a 
fluid and polymer mucoadhesion. As a result, the MRT value would drop 
below that resulting from instillation of less viscous eyedrops. Thus, in 
such cases as those of HEC and HA 0.7% w/v, the particular conditions of 
the in vivo environment make up an uncontrollable variable that makes in 
vitro methods, such as the present one, inadequate to comparatively 
predict mucoadhesion and residence time of different polymers in the 
precorneal area. 
The curves of polymer elimination from tear fluid are presented in Figure 
V.1.a-c. They generally show an exponential decay, in line with the usual 
trend of xenobiotic clearance from precorneal area. Exceptionally TSP 
0.7% w/v, which shows the highest MRT value of all polymers in Table 
V.1., also shows an almost constant elimination rate in Figure V.1.c. Such 
a unique behaviour is believed to be due to a comparatively strong 
adhesion of this polysaccaride to the ocular surface at this concentration. 
 
V.3.2 Polysaccharide Effect on Drug Residence in Tear Fluid of 
Rabbits 
 
V.3.2.1 Case of KF 
The KF concentration of 0.7 mg/ml in ophthalmic drops was equal 
to that contained in the commercial product Ketoftil (Farmigea, Italy). The 
95 
 
  
polysaccharides tested were TSP, HA and HEC at the concentration of 
0.2% w/v, and TSP and HA at 0.7% w/v. HEC was not tested at the latter 
concentration because a phase separation was observed in the solution 
containing KF and HEC in PBS. The relevant drug elimination profiles can 
be seen in Figure V.2., while the residence times in tear fluid are found in 
Table V.2., where the drug fraction bound to polymer, as determined by 
dynamic dialysis, is also reported. 
It appears from data in the table that the effects of the polymer 
concentration of 0.2% w/v on either the MRT or RTmax values for KF are 
generally insignificant except with TSP, in the presence of which the MRT 
value is significantly higher than that for the control. On the other hand, at 
the concentration of 0.7% w/v the polymers show enhancing effects on 
both MRT and RTmax with respect to the control, the strongest effect being 
exerted by TSP. An effect of TSP to slow down KF elimination from tear 
fluid is also apparent in Figure V.2.b, where the relevant CTF vs. time 
profile shows a plateau at 4-8 min, quite unlike all other cases. It results 
from a comparison of MRT values in Tables V.2. and V.3. at 
corresponding polymer concentrations that the residence of each polymer 
in the tear fluid of rabbits is longer than that of the drug. This can be given 
the following explanation. TSP, HA and HEC have shown an 
adhesiveness to the eye surface that should slow down their removal from 
tear fluid. 
Although these polymers are expected to stabilize the tear film, thereby 
prolonging the drug residence in the precorneal area, the residence time 
of the drug is not expected to be so long as that of the mucoadhesive 
polymer, also considering that the fB values in Table V.2. in no case point 
to any strong drug-polymer binding.  
 
V.3.2.2 Case of DS 
Diclofenac is chemically quite different from ketotifen, e. g., the 
former is an acid, the latter a base. Yet, the data on DS residence in 
precorneal area, reported in Table V.3., and on DS elimination kinetics 
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from such an area, presented in Figure V.3., show some similarities with 
the corresponding data for KF, discussed in the preceding section. Thus, 
as already observed with KF, also with DS it appears that only in the case 
of TSP is the polymer effect on drug MRT statistically significant at 0.2% 
w/v polymer concentration, and that, at 0.7% w/v polymer concentration, 
TSP exerts the strongest effect of all polymers on drug MRT. The values 
of this parameter, as appear in Tables 16 and 17 for TSP 0.7% w/v are 
similar for KF and DS. The same similarity is observed when HA 0.7% w/v 
is the polymer. Also worth stressing is the similarity between the 
elimination profiles of KF and DS in the presence of 0.7% w/v TSP, 
appearing in Figures V.2.b and V.3.b. These observations suggest that a 
polymer, if mucoadhesive, exerts a paramount influence on the residence 
time of a drug in the precorneal area, irrespective of the chemical nature of 
the drug. A consideration of the fB values in Table V.3. suggests that in 
none of the cases tested was the molecular drug-polymer binding so 
strong as to be determinant to the polymer effect on drug MRT. It was 
probably the stabilization of tear film by the mucoadhesive polymer that 
mostly delayed drug elimination from the eye surface compared to the 
polymer-free control. 
 
V.4 Conclusions 
The comparative evaluation of the ability of the different 
polysaccharides studied to resist removal from tear fluid has suggested 
that the optimal polymer to be used as an additive in ophthalmic drops 
should be mucoadhesive without increasing the viscosity of the solution to 
an excessive extent. TSP 0.7% w/v has shown to possess more of these 
properties than the other polymers at comparison, in fact, it has exhibited 
the highest MRT value. HA and HEC, although mucoadhesive, increase 
the solution viscosity to an excessive degree, and this, in addition to 
worsening the patient compliance, could induce an anomalous reflex 
tearing with consequent acceleration of precorneal clearance. In virtue of 
its mucoadhesiveness, TSP 0.7% w/v is supposed to stabilize the tear film. 
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Perhaps this is the main reason why the MRT and RTmax of the two 
different drugs tested in the present work were significantly prolonged by 
TSP 0.7% w/v. The present results have shown a prospect of future 
ophthalmic formulations of KF and DS allowing a decreased frequency of 
instillations. 
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TABLES 
 
 
Table V.1. – Comparison between the polysaccharide effect on the viscosity of the 
mucin-polysaccharide dispersion and the mean residence time of polysaccharide in tear 
fluid of rabbits. Cp, polysaccharide concentration; ηp, polysaccharide viscosity; ηmp, 
viscosity component of the mucinpolysaccharide dispersion due to mucin-polymer 
interaction; ηmp/η, contribution of the interactive component to the viscosity of the 
mucinpolysaccharide system; MRT, mean residence time of polysaccharide in tear fluid 
of rabbits. 
 Polymer  Cp, % w/v  ηpa, mPas  ηmpa, mPas  ηmp/ηa, % MRT±ES, min 
 
 TSP 
 0.2  1.85*  44.7  20.4  7.35±0.77 
 0.5  4.45  63.5  22.1  10.42±1.70 
 0.7  9.88  94.0  32.7  18.09±1.55 
 
 HA 
 0.2  2.11  32.7  15.7  6.50±1.16 
 0.5  15.0  54.0  18.6  14.48±2.56 
 0.7  53.5  140.3  38.0  11.51±1.76 
 
 HEC 
 0.2  2.88  45.1  20.3  8.49±0.98 
 0.5  12.3  82.7  26.3  14.68±2.79 
 0.7  59.7  146.1  38.5  13.44±2.37 
aViscosity measurements carried out at 35 °C. Values marked by * refer to a newtonian, 
non-marked ones to a pseudoplastic behaviour (shear rate, 200 s-1). 
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Table V.2. – Polysaccharide effect on the residence time of KF in tear fluid of rabbits. 
Cp, polymer concentration in eyedrops; MRT, mean residence time; RTmax, maximum 
residence time at measurable concentrations (≥1.1 µg/ml); fB, drug fraction bound to 
polymer. 
Polymer   Cp, % w/v   MRT±ES, min   RTmax, min   fB, % 
Control   -   5.07±0.46   12   - 
TSP   0.2   5.94±0.29*   12   8 
   0.7   9.14±0.38*   30   9 
HA   0.2   5.74±0.38   12   12 
   0.7   6.97±0.62*   20   12 
HEC   0.2   4.42±0.33   10   n.s.a 
aNot significant.  
*Value significantly different from control (P<0.05). 
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Table V.3. – Polysaccharide effect on the residence time of DS in tear fluid of rabbits. 
Cp, polymer concentration in eyedrops; MRT, mean residence time; RTmax, maximum 
residence time at measurable concentrations (≥1.5 µg/ml); fB, drug fraction bound to 
polymer. 
Polymer   Cp, % w/v   MRT±ES, min   RTmax, min   fB, % 
Control   -   5.55±0.21   20   - 
TSP   0.2   6.47±0.61*   20   13 
   0.7   8.18±0.89*   35   12 
HA   0.2   5.85±0.42   20   9 
   0.7   6.85±0.44*   35   21 
HEC   0.2   6.25±0.58   20   n.s.a 
   0.7   6.05±0.30   20   18 
aNot significant.  
*Value significantly different from control (P<0.05). 
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure V.1. – Profiles of polysaccharide elimination from tear fluid of rabbits following 
instillation of ophthalmic drops containing 0.2 (a), 0.5 (b) and 0.7 (c) % w/v polymer. 
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Figure V.2. – Profiles of KF elimination from tear fluid of rabbits following instillation 
of medicated ophthalmic drops containing 0.7 mg/ml drug and 0.2 (a) or 0.7 (b) % w/v of 
different polysaccharides. 
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Figure V.3. – Profiles of DS elimination from tear fluid of rabbits following instillation 
of medicated ophthalmic drops containing 1.0 mg/ml drug and 0.2 (a) or 0.7 (b) % w/v of 
different polysaccharides. 
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